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Revision of a full-length Article 
 
Dear Editor, 
 
Through this letter, we would like to ask you to consider our manuscript entitled “Simultaneous quantitative profiling of 
20 isoprostanoids from omega-3 and omega-6 polyunsaturated fatty acids by LC-MS/MS in various biological 
samples.” for revision and publication in Analytica Chimica Acta. 
 
We tried to address all the questions where possible, and clarify in the manuscript. We hope that our modifications coult 
permit our method to be published in your journal. 
 
Sincerely, 
 
Dr Justine BERTRAND-MICHEL 
            
- Lipidomique - 
Cover Letter(including Novelty Statement)
 Responses to reviewers: 
We thank the reviewers for the valuable suggestions, and we have tried to address all the 
questions where possible, and clarify in the manuscript. Our answers to the referees are in bold in 
the text, and the text modification are in red in the manuscript. 
Reviewer #1: This manuscript describes the identification and quantitative profiling of isoprostanoids 
by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using either derivatization or two 
different derivatization protocols of the carboxylic acid function. 
The manuscript is interesting and provides an additional answer to investigate the identification of 
isoprostanoids, which are a group of non-enzymatic oxygenated metabolites of polyunsaturated fatty 
acids. It is clearly important to improve our understanding of these metabolites and it is arguably 
equally important the need of selective and sensitive analytical methods. 
There are some comments/suggestions that deserve clarification: 
 
1) at page 9, paragraph 3.1.1. It is stated that (i) "IsoPs analyzed in this study have different 
structures comparatively" (ii) "one specific fragment was selected for each compound and the 
collision energy was optimized for each SRM transition". Considering that the CID fragmentation of 
these metabolites has not been discussed and no references are given, how have the Authors choice 
the SRM transitions? 
For each pure molecule: first, the full scan was performed to observe the main ion formed in our 
MS system, then a product ion spectrum was done to select the most abundant daughter ion to 
keep for the MRM transition; and finally the collision energy was optimized for this transition. The 
text of the manuscript has been slightly modified to explain this point (paragraph 3.1.1). As 
majority of these molecules have never been described previously (except for few of them : 
references :  [25]), it is difficult to make comparisons with some of the new ones in this study. 
 
2) Figure 3. All these plots are not easy to follow and a more explicative view is recommended. 
The view has been amended and the name of each molecule has been added, so it should be 
clearer now. 
 
3) Page 10, line 57. What's the meaning of "using linear regression model with different weight 
factors." Especially the meaning of different weight factors deserve an explanation. What, where and 
when have weight factors been applied? 
We apologize for the mistake. The linear regression model used the classical 1/X weight factor. It 
has been modified in the text in the paragraph 3.1.3. 
 
4) Whereas several tabulated data are reported in the manuscript, no one biological sample as an 
example of LC/MS/MS separation is reported; 
*Response to Reviews
As it was difficult to show profile for all different biological samples we measured, we decided to 
show only human plasma in figure 5, which was the sample used for validated our method. It is 
also important to display human plasma profile to allow clinical scientists and biochemists to be 
able to compare their measurements in human plasma with ours. The text (paragraph 3.4) was 
modified to note this additional figure. 
 conversely, several redundant Tables are included, namely 2, 3, 4 and 5 which should be moved in 
the supporting information. 
It is true that there are many tables in this paper which present different steps for validation of the 
method. We think tables 2 and 3 are important information to be conserved close to the text. 
However, we propose to transfer tables 4 and 5 as supporting materials and indicate them as 
tables 1 and 2. This has been changed in the text paragraph 3.3.1. Table 6 (in first version) is re-
numbered as table 4 in this new version.  
 
5) Table 3. I have serious doubts about the consequence of data like LOD and LOQ. What is the 
reliability of data such as ".. the LOD values ranged from 0.49 ng/mL to 15.6 ng/mL and the LOQs 
from 0.98 ng/mL to 31.25 ng/mL." without standard errors and a confidence level (Table 3). 
Calibration curves were performed for 14 concentrations : 0.06, 0.12, 0.24, 0.49,  0.98, 1.95, 3.91, 
7.81, 15.63, 31.25, 62.5, 125, 250, and 500 ng mL-1 for all primary standards (in fact 500ng/mL 
division by two). The values considered for LOQ at lower point was s/n>10 and for LOD, the lower 
point was s/n > 5. This determination is common for analyst to obtain LOD and LOQ values. This 
information has been added in the text (paragraph 2.2). 
 
6) And data of Table 4; how many samples were examined and what is the meaning of error of matrix 
effect and extraction yield ? 
The experiment for matrix effect and yield extract calculation were performed in triplicate (of 
three different samples) and these three different preparation were injected in triplicates. We did 
not describe both matrix effect and extraction yield clearly in the manuscript and it has been 
corrected in paragraphs 2.8 and 3.3. 
 
7) Another critical points is present in the data presented in Figure 6C and D. Need they really to be 
displayed or just a comment it is enough? 
We agree that this figure doesn't add any information to the manuscript. We have removed the 
information and  replaced in the text with the mention " data not shown".  
 
8) Page 14, Conclusions. Are really conclusions or an abstract is reported? If you look at lines 9-19, it 
seems a summary of what it is presented in the Abstract! 
 
We have moved the original content of the conclusion to discussion. A new and precise conclusion 
has been added in the manuscript. 
  
Reviewer #2: This manuscript described a LC-MS/MS methodology for quantification of several 
isoprostanes  in very low concentration. The authors optimized their analytical method in many 
ways, from LC separation of isomers to derivatization conditions for increasing the signals in SRM 
analysis, which eventually brought the appropriate method to complex biological samples for 
application test. In general, the manuscript is well organized and the explanation for each step is very 
clear. I have only minor suggestions for the author to consider. 
1) Figure 1, some annotations of the molecules are on top of the structure, please rearrange it so 
that it's clear to see. 
The format of the figure has been improved, it should be easier to read now. 
 
2) Figure 2, the TIC for PA derivatization and HP derivatization were illustrated using both dotted 
lines, one is large and one is small. It would easier to compare and distinguish if different colors are 
used, or with more different lines types. 
3) It would be easier for the audiences to follow if the author gives two examples of HP and PA 
derivatization using any of the IsoPs molecules mentioned. One formed a hydrazide and the other 
formed an amide bond during derivatization. The structures can be combined into Figure 2 on top of 
the chromatogram lines, or separate out into a new figure. 
Figure 2 has been improved, the structures of PA and HP derivatized are added on the figure. 
 
4) The yield of extraction of F3t-IsoPs was above 100%, which should be round to 100%, since any 
numbers beyond 100% is meaningless in terms of yield. 
We agree to this. However, as we are determining 20 different molecules simultaneously and using 
response ratio with deuterated molecules for quantification, the extraction yield should not be the 
primary confounding factor. 
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*Graphical Abstract
Highlights : 
 
Isoprostanoids are a group of non-enzymatic oxygenated metabolites of polyunsaturated fatty acids 
which are key intermediates in a lot of physiological mechanism. An quantitative LC-MS/MS profiling  
of these biomarkers was developed, validated and applied it on various biological sample. This 
method will be highly useful to follow biological process dealing with ROS. 
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Abbreviations:  
AA : Arachidonic acid 
AdA : Adrenic acid 
ALA : -Linolenic acid 
BHT : Butylated hydroxytoluene 
CSF : Cerebrospinal fluid 
DHA : Docosahexaenoic acid 
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DPDS : 2,2’-dipyridyl disulfide 
AGTA : Ethylene glycol tetra acetic acid 
EPA : Eicosapentaenoic acid 
ESI : Electrospray ionization 
HP : 2-hydrazinopyridine 
HPLC : High-pressure liquid chromatography 
IsoPs : Isoprostanes 
LOD : limit of detection 
LOQ : limit of quantification 
m/z : Mass-to-charge ratio 
MRM : Multiple reaction monitoring 
MS : Mass spectrometry 
NeuroPs : Neuroprostanes 
OS : Oxidative Stress 
PhytoPs : Phytoprostanes 
PA : 2-picolylamine 
PUFAs : Polyunsaturated fatty acids 
ROS : Reactive oxygen species 
SPE : Solid-phase extraction 
SRM : Selected-reaction monitoring 
S/N : signal to noise ratio  
TPP : Triphenylphosphine 
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Abstract 
Isoprostanoids are a group of non-enzymatic oxygenated metabolites of polyunsaturated fatty acids. It belongs to oxylipins group, which are 
important lipid mediators in biological processes, such as tissue repair, blood clotting, blood vessel permeability, inflammation and immunity 
regulation. Recently, isoprostanoids from eicosapentaenoic, docosahexaenoic, adrenic and -linolenic namely F3-isoprostanes, F4-
neuroprostanes, F2-dihomo-isoprostanes and F1-phytoprostanes, respectively have attracted attention because of their putative contribution to 
health. Since isoprostanoids are derived from different substrate of PUFAs and can have similar or opposing biological consequences, a total 
isoprostanoids profile is essential to understand the overall effect in the testing model. However, the concentration of most isoprostanoids range 
from picogram to nanogram, therefore a sensitive method to quantify 20 isoprostanoids simultaneously was formulated and measured by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). The lipid portion from various biological samples was extracted prior to LC-MS/MS 
evaluation. For all the isoprostanoids LOD and LOQ, and the method was validated on plasma samples for matrix effect, yield of extraction and 
reproducibility were determined. The methodology was further tested for the isoprostanoids profiles in brain and liver of LDLR
-/-
 mice with and 
without docosahexaenoic acid (DHA) supplementation. Our analysis showed similar levels of total F2-isoprostanes and F4-neuroprostanes in the 
liver and brain of non-supplemented LDLR
-/-
 mice. The distribution of different F2-isoprostane isomers varied between tissues but not for F4-
neuroprostanes which were predominated by the 4(RS)-4-F4t-neuroprostane isomer. DHA supplementation to LDLR
-/-
 mice concomitantly 
increased total F4-neuroprostanes levels compared to F2-isoprostanes but this effect was more pronounced in the liver than brain.  
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1. Introduction  
Excessive free radicals in vivo have been implicated in a number of human diseases such as neurodegenerative, cardiovascular, pulmonary disorder and 
cancer[1] [2]. The most common free radicals are reactive oxygen species (ROS), which can modify lipids, proteins and nucleic acids. Of the lipids in 
particular, the polyunsaturated fatty acids (PUFA) form a wide variety of oxygenated metabolites [3] [4]. Among them, the isoprostanes (IsoPs) 
appears to be a promising group of biomarkers to be assessed for oxidative stress (OS) assessment in vivo for over two decades due to its specificity and 
sensitivity[5] [6]. These compounds are formed in situ on membrane phospholipids and then released into their free form via phospholipase A2 and 
platelet activating factor hydrolase for circulation. Elevation of IsoPs, in particular those originated from arachidonic acid (AA, 20:4 n-6) also 
known as F2-IsoPs in biological fluids (e.g. plasma and urines) are recognized as the reference biomarker for lipid peroxidation and OS in most 
biological systems. Beyond their capacity of OS as biomarker, IsoPs from n-3 PUFA also demonstrated to be biologically active[7] [8] [9]. 
Therefore it is crucial to be able to quantify the different isoforms in a large panel of biological samples to integrate this chemical and biological 
complexity.  
Unlike PUFAs, the isoprostanoids are quite complex to assess since the concentration range is very low (from picogram to nanogram) in most 
biological samples. Moreover, depending on the parent PUFAs, a large diversity of molecule has been discovered as shown in Figure 1. Analysis 
of these metabolites in biological samples is a challenge and depends on the robustness of the analytical instrumentation. Further, it requires one 
or several preparation steps, including hydrolysis and extraction from their biological matrix before analysis by radio immunological methods 
(RIA) or gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS), which are often coupled to 
another mass spectrometer (MS/MS) to increase the sensitivity[10]. It is well known to analysts, that RIA is not specific enough to provide 
efficient quantification of different IsoPs [11] To date, LC-MS/MS is the most common technique to quantify these biomarkers [12], even if the 
mass spectrometry is not the perfect method to perform absolute quantification compared to GC-MS because of the various ionization efficiency 
between different molecules. These changes can be very important when comparing compounds with very close structures especially for lipids 
including the IsoPs. In order to optimize ionization efficacy for each compound, it is essential to have the pure standard to develop a rigorous 
quantitative method. Although some standards are available commercially, many of the novel ones are unavailable. Through total synthesis, 
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Durand’s group was able to synthesize [13-21] these novel standards, for example dihomo-IsoPs from adrenic acid (C22:4 n-6, AdA) for mass 
spectrometry analysis.  
In this study, we developed a complete quantitative profiling of IsoPs by LC-MS/MS. As IsoPs are present in a very low concentration it was 
imperative to improve largely the sensitivity of the method therefore we also tried two different derivatization procedures of the carboxylic acid 
function to improve the ionization of molecules. For both profiles, with and without derivatization, chromatographic separation has been 
optimized and sensitivity compared. The two methods have been tested on human plasma and the best one was applied in this study. The final 
methodology was then validated on plasma sample and applied to other biological samples, namely cerebrospinal fluid (CSF), urine, and brain, 
liver and muscle tissues. Our methodology was finally checked on a mouse model, in which the goal was to determine the isoprostanoids 
profiling in the brain and liver of LDLR
-/-
 mice and to investigate the effect of docosahexaenoic acid (C22:6 n-3, DHA) supplementation on these 
profiles.  
 
2. Material and methods 
2.1. Chemicals 
Commercially available IsoP standards (d4-15-F2t-IsoP and 2,3-dinor-15-F2t-IsoP) were purchased from Cayman Chemicals (Ann Arbor, MI, 
USA). Others standards Ent-16-epi-16-F1t-PhytoP, Ent-16-F1t-PhytoP, 9-F1t-PhytoP, 9-epi-9-F1t-PhytoP, Ent-15(RS)-2,3-dinor-5,6 dihydro-15-
F2t-IsoP, 8-F3t-IsoP, 8-epi-8-F3t-IsoP, 5-F3t-IsoP, 5-epi-5-F3t-IsoP, 15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, 5-epi-5-F2t-IsoP, 10-F4t-NeuroP, 
10-epi-10-F4t-NeuroP, 14(RS)-14-F4t-NeuroP, 4(RS)-4-F4t-NeuroP, Ent-7(RS)-7-F2t-dihomo-IsoP, 17(RS)-17-F2t-dihomo-IsoP, C21-15-F2t-IsoP, 
d4-10-epi-10-F4t-NeuroP, d4-10-F4t-NeuroP, d4-4(RS)-4-F4t-NeuroP were synthestized according to our published procedures
13 
.Hexane, ethanol 
absolute, acetic acid potassium hydroxide (KOH), methanol (MeOH; HPLC gradient Grade), butylated hydroxytoluene (BHT) and formic acid 
were purchased from Sigma Aldrich (Saint Quentin Fallavier, France). Acetonitrile (ACN; HPLC grade) was obtained from Acros Organics 
(Illkirch, France). Ammonia solution 30 % (NH4OH) was purchased from Carlo Erba Reagenti (Cornaredo, Italy). Water used in this study was 
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purified on a milliQ system (Millipore). The 96 well-plate for solid extraction (SPE) (Oasis Max, 60 mg) was purchased from Waters (Saint-
Quentin en Yvelines, France). 
 
2.2. Standards preparation for linearity and reproducibility assessment 
Standard solutions with or without derivatization were prepared in MeOH at the following concentrations, 0.06, 0.12, 0.24, 0.49, 0.98, 1.95, 3.91, 
7.81, 15.63, 31.25, 62.5, 125, 250, and 500 ng mL-1 for all primary standards. The concentration of the deuterated internal standards (IS) used 5 
ng taken from 250 ng mL-1 stock solution. Calibration curves were calculated by the area ratio of the analyte and the internal standard. The 
linearity and the accuracy of the detection were determined and the limit of detection (LOD : lower point with s/n > 5) and limit of quantification 
(LOQ: lower point with s/n > 10) were defined for the 20 compounds.  
 
2.3. Biological fluid extraction 
Healthy human plasma (1 mL) or CSF (600 L), LDLR-/- mice plasma (≥200 L) or urine (≥200 L) were collected, and supplemented with 
BHT (1% in ethanol), and stored at -80°C. For the extraction, the samples were thawed and spiked with 5 ng of each internal standard. A volume 
of 985 µL of hydrolysis solution (KOH 1M in MeOH) was added. The resulting mixture was mixed and incubated at 40°C for 30 minutes 
(excepted for urine). After cooling in room temperature, 2 mL of 40 mM formic acid (pH 4.5 adjusted with 1 M NaOH) was added. Thereafter, 
the samples including urine were cleaned and extracted by solid-phase extraction (SPE) on 96-well plate OASIS MAX 60 mg (Waters, USA) 
modified from Lee et al. method [22]. Briefly, the wells were cleaned with 2 mL of MeOH and conditioned with 2 mL of 40 mM formic acid (pH 
4.5). After loading the samples, the wells were washed with 2 mL of 2% NH4OH followed by 2 mL of MeOH/20 mM formic acid (20:80 v/v) 
and 2 mL of hexane. The IsoPs were eluted with 2 ml hexane/ethanol/acetic acid (70:29.4:0.6 v/v/v). After drying under nitrogen gas, the 
samples were re-dissolved with 20 µL of MeOH. A part of the sample (5 l) was taken for LC-MS/MS analysis and the remaining samples were 
derivatized prior to LC-MS/MS measurement. 
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2.4. Biological tissue preparation 
The tissue samples were stored at -80°C before preparation. To a total of 200 mg of thawed tissue (brain, liver or muscle) sample, 1 mL of Folch 
solution (CHCl3:MeOH, 2:1,  v/v) containing 10 µL BHT (1 % in ethanol) was added and spiked with 5 ng of each internal standard.  The 
mixture was homogenized with a Fast Prep instrument (MP Biomedicals) for 30 s at 6.5 m/s. Then the homogenized tissue was further extracted 
with 1.5 mL ice-cold Folch solution (CHCl3: MeOH, 2:1, v/v) and 0.5 mL of ultrapure water. The mix was shaken for 30 s and centrifuge for 10 
min at room temperature to separate the aqueous and organic layers. The lower organic layer was carefully removed and transferred to a pyrex 
tube and then evaporated under nitrogen gas. The extracted lipid was dissolved in 1 mL of hydrolysis solution (KOH 1M in MeOH) and 
incubated at 40°C for 30 minutes. After cooling in room temperature, 3 mL of 40 mM formic acid was added. The samples were then cleaned 
and extracted by SPE as described in section 2.3. 
 
2.5. Derivatization of the extracted samples 
To a set of extracted samples, 10 µL of freshly prepared solution of 10 mM triphenylphosphine (TPP), 10 mM 2,2’-dipridyl disulfide (DPDS) 
and 10 µg 2-picolyamine (PA) prepared separately in acetonitrile were added successively. To another set of the extracted samples, freshly 
prepared 10 µL of TPP and DPDS, and 10 µL of freshly prepared 10 µg 2-hydrazinopyridine (HP) in acetonitrile were added. The sample 
mixture was incubated at 60°C for 10 min. The mixture was dried under nitrogen and then reconstituted in MeOH for LC-MS/MS analysis.  
 
2.6. LC-MS/MS analysis 
High performance liquid chromatography (HPLC) was performed using an Agilent 1290 Infinity equipped with a thermostated autosampler, a 
binary pump and a column oven. The analytical column was a Zorbax SB-C18 Rapid Resolution HD (2,1 x 100 mm; 1,8 µm) (Agilent 
Technologies, USA) and maintained at 25°C. The mobile phases consisted of water: formic acid (99.9:0.1;v/v) (A) and acetonitrile : formic acid 
(99.9:0.1, v/v) (B). The linear gradient was set as follows for the non-derivatized IsoPs analysis: 20% B at 0 min, 30% B at 15 min, 35% B at 20 
min, 100% B at 23 min, 100% B at 26 min, and 20% B at 26.5 min for 1.5 min of equilibration. For the derivatized IsoPs, the gradient was set to 
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18% B at 0 min, 30% B at 22 min, 35% B at 26 min, 100% B at 28 min, 100% B at 29 min, and 18% B at 29.5 min for 1.5 min of equilibration. 
The flow rate was set at 0.3 mL/min. The autosampler was fixed at 5◦C and the injection volume was 5 µL per analysis. The HPLC system was 
coupled on-line to an Agilent 6460 triple quadrupole MS (Agilent Technologies, USA) equipped with electrospray ionization (ESI). The ESI was 
performed in negative ion mode for non-derivatized IsoPs and positive mode for derivatized IsoPs. The MS source parameters were set as 
follows: source temperature 325ºC, nebulizer gas (nitrogen) flow rate 10 L min-1, sheath gas temperature 350ºC, sheath gas (nitrogen) flow rate 
12 L min-1 and the spray voltage adjusted to −3000 V. The dwell time used was 10 ms. The analysis was performed in Selected Reaction 
Monitoring (SRM) detection mode using nitrogen as the collision gas. The SRM of each compound without (Table 1) or with derivatization 
(Table 2) were pre-determined by MS/MS analysis. Peak detection, integration and quantitative analysis were performed by Mass Hunter 
Quantitative analysis software (Agilent Technologies, USA). Concentration of the analytes was calculated by calibration curves obtained in 
Section 2.2.  
 
2.7. Accuracy and precision 
Repeatability and precision were respectively assessed using relative standard deviation (% RSD) and accuracy at 3 concentrations (3.91, 31.25 
and 250 ng mL-1) of pure standards in triplicate determination. The concentration was subsequently calculated using the standard curves 
generated. For inter-day variation, the samples were analyzed on 2 different days, with 15 days in between interval. 
 
2.8. Validation of sample preparation 
The preparation of human plasma sample was validated through the yield extraction and the matrix effect. Briefly, three sets in triplicate were 
prepared :  500 µL of plasma (n = 3) were spiked with 5 ng of IS stock solution and 2 different concentrations of standards (31.25 and 250 ng 
mL-1) and were extracted as described in Section 2.3: 1) 500 µL of plasma (n = 3) were extracted and then spiked with 5 ng of IS stock solution 
with 2 different concentrations of standards (31.25 and 250 ng mL-1), and 2) a separate set of pure 5 ng of IS stock solution and standards 
solutions (31.25 and 250 ng mL-1) in the absence of plasma extract were prepared in MeOH. All sets (of three samples) were analyzed in 
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triplicate using the LC-MS/MS. The yield extraction was determined as the percent difference between peak areas of standards in pre-spiked and 
post-spiked samples. The matrix effect was determined as the percentage difference between peak areas of standards added to the extracted 
samples and pure standard. The plasma matrix effect and yield extraction were calculated for each compound measured in the method described. 
 
2.9. Biological samples 
 
With permission, a sub-group of LDLR
-/-
 mice from a previous study [23] was used to determine the effect of DHA supplementation on the 
profile of the isoprostanoids in the brain and liver. Briefly, from 8 weeks of age and for 20 weeks, the mice received by daily oral gavages (50 
L, 5 days/week) either oleic acid rich sunflower oil (Lesieur, Asnières-sur-Seine, France; Control group) or a mixture of oleic acid rich 
sunflower oil and DHA rich tuna oil (OMEGAVIE DHA90TG, Polaris Nutritional Lipids, France containing 90% of DHA as TG) providing 2% 
(or 35.5 mg/d/mouse) of energy as DHA. At the end of the supplementation, the mice were anaesthetized (40 mg pentobarbital/kg body weight) 
and the tissue samples were rapidly removed and snap-frozen in liquid nitrogen and stored at -80°C until analysis. Quantification of DHA and 
AA were performed on brain and liver sample. In brief, after an organic extraction in presence of internal standard, the total fatty acid were 
methylated, analysed and quantified on a gas chromatography-flame ionization detector (GC-FID) system [24]. 
 
3. Results and discussion  
3.1 LC-MS/MS method development 
In order to achieve the necessary selectivity and sensitivity of the method, the mass detection and chromatographic separation of each standard 
with or without derivatization were individually optimized.  
3.1.1 Mass detection 
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IsoPs analyzed in this study have different structures comparatively. Nevertheless, due to their common carboxylic acid moiety, they were all 
detected in the negative ion mode as [M−H]− ions. Firstly, the fragmentor voltage was optimized for each compound in product ion scan mode. 
This parameter promotes the transmission of the ions between the ionization source and the first quadrupole. Low voltages lead to poor 
transmission efficiency whereas too high voltage values lead to excessive fragmentation. The optimum value corresponded to a maximum 
transmission of the [M−H]− ions without fragmentation. The second optimized parameter was the collision energy for each MS/MS transition to 
monitor; the most abundant one was selected. In this study, one specific fragment was selected for each compound and the collision energy was 
optimized for each SRM transition (Table 1). SRM transitions observed for this study are divided according to the PUFA type, that includes 15-
F2 series (m/z 353 to m/z 193), 5-F2 series (m/z 353 to m/z 115), 8-F3 series (m/z 351 to m/z 127), and 5-F3 series (m/z 351 to m/z 115) [25]. For 
the F1-PhytoP, the carboxylate portion was lost to give SRM m/z 327 to m/z 283, whereas 10-F4-NeuroP seems to fragment in the same way as 
8-F3 series (m/z 377 to m/z 153). For the remaining compounds, the fragmentations were not as definite. 
Since the concentration of the IsoPs is low in biological samples, analysts may opt for a derivatization procedure to increase the volatility and 
polarity of the compounds. To enhance the detection responses of carboxylic acids in ESI-MS/MS several chemical derivatization procedure can 
be applied and measured in the positive mode of the LC-MS/MS[26] [27]. However, the derivatization reagents are not always commercially 
available and the preparation can be long and time consuming. In our study, we tested two simple reagents 2-hydrazinopyridine (HP) and 2-
picolylamine (PA),  which can be derivatized in one step under mild conditions[28]. When the reagents react with the acidic function of the 
IsoPs, the HP and PA form a hydrazide and an amide bond, respectively. The sensitivity obtained was preferably for PA derivatives than HP 
derivatives (Figure 2), therefore MS parameters were optimized only for PA (Table 2). An important drawback of this derivatization method is 
that for all species a unique PA fragment of m/z = 109 is obtained, which creates poor specificity of the IsoP tested. 
 
3.1.2 Chromatographic separation 
The IsoP determined in this study have similar molecular mass and structure. As a result, the liquid chromatographic separation of each 
metabolite is a crucial step where each isomer of the IsoPs needs to be optimized to be separated in the chromatogram for detection.  In this 
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study, the eluent phase was acidic and a semi-linear gradient elution allows the chromatographic resolution of most compounds on a 10 cm C18 
reverse phase column within 30 minutes. The gradient was also designed for the measurement of PA derivatives. As shown in Figure 3, F1t-
PhytoPs eluted first, followed by 2,3-dinor-15-F2t-IsoP, F3t-IsoPs, F2t-IsoPs, then F4t-NeuroPs and F2t-dihomo-IsoPs. The isobaric compounds 
bearing the same transition such as F1t-PhytoPs were successfully separated (Table 1). Furthermore, all the isomers were resolved in the 
chromatographic separation including 8-F3t- and 8-epi-8-F3t-IsoPs (Figure 4A and B), while for 5-F2t- and 5-epi-5-F2t-IsoPs the separation 
between the two peaks showed an overlap at the tail of the chromatographic peak (Figure 4C and D). The separation was comparable with PA 
derivatives indicating derivatization procedure did not improve the separation. 
 
3.1.3 Sensitivity 
To quantify our isoprostanoids we first had to choose the appropriate internal internal standard for each metabolite. NeuroPs and 15-F2t-IsoP 
were quantified through their deuterated equivalent and for other IsoPs, d4-15-F2t-IsoP and C21-15-F2t-IsoP were used.  Based on the internal 
standard, each calibration curve was obtained with 10 concentrations of the pure IsoPs ranging from 0.9 to 500 ng/mL. The curves were fitted 
using linear regression model with 1/X factors. The linearity of the method was assessed for each metabolite by evaluating the correlation 
coefficient (Table 3). The LOD and LOQ of our method were evaluated, and in general LOD corresponding to the lowest concentration had 
signal to noise ratio above 3 and LOQ corresponding to the lowest concentration had signal to noise ratio above 10. Both of these values however 
depended on the type of isoprostanoids. For PA derivatives the LOD values ranged from 0.24 ng/mL to 1 ng/mL and the LOQs from 0.12 ng/mL 
to 2 ng/mL. As shown in Table 3, the LOD values ranged from 0.49 ng/mL to 15.6 ng/mL and the LOQs from 0.98 ng/mL to 31.25 ng/mL. The 
sensitivity obtained for F2-IsoP, which is the main IsoP in the literature, is in agreement with LOQ previously reported by others  [29] [30]. The 
sensitivity observed was better than the isoprostanoids with derivatization, in particular for PA. The lack of sensitivity and specificity by PA 
derivatization indicates that it was not suited for the analysis of IsoPs and more so in biological samples, which often have complicated matrix 
structure that could further affect the precision of the measurement. 
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3.2 Plasma sample preparation and analysis   
The lipid portion of the tissues or cells was extracted using Folch solution in the presence of antioxidant (0.005% BHT). It is known 
approximately 70% of the IsoPs are conjugated to phospholipid through ester bond [31], therefore hydrolysis step is required to analyse the total 
concentration.  The lipid extract or fluid (except urine) was treated with 1 M KOH prepared in methanol for 30 minutes at 40 ºC. This step is not 
required for measurement of non-esterified IsoPs i.e. free form. A purification process is needed to reduce matrix effect and to increase 
sensitivity of the quantification by LC–MS/MS analysis. Different SPE cartridges were tested in this procedure namely, C18[32], HRX[33] and 
MAX[22]. It was found MAX cartridge, which is composed of mixed anionic exchange phase provided the cleanest sample and the best LC-
MS/MS evaluation. A part of the lipid extracts from SPE were taken for derivatization process. The data obtain from plasma with and without 
derivatization were compared (data not shown). Despite the peak response and area being bigger for the derivatized samples, the background 
noise of the chromatogram was much more compared to the non-derivatized samples. Moreover, the derivatization caused the formation of few 
additional peaks very close to the target ones, making it more difficult to differentiate for peak integration. This observation further support that 
derivatization procedure is not suitable for IsoP analysis by LC-MS/MS for plasma and likely for other biological samples. Therefore, in order to 
avoid overestimation in our quantification, we adopted the IsoP measurements without derivatization process in this study.  
 
3.3 Validation of sample processing 
3.3.1 Matrix effect and yield of extraction  
The efficiency of the sample processing was assessed by measuring the matrix effect and the extraction yield using plasma in triplicate. These 
two parameters were calculated for two concentrations of IsoPs (250 and 31.25 ng/mL). The peak areas of the chromatogram for each IsoP were 
compared before and after addition plasma extraction to obtain the matrix effect, as summarized in supporting material Table 1.  The matrix 
effect ranged between 51.4% to 92.7% for low concentration and between 56.7% to 77.5% for high concentration. The values were relatively 
homogeneous in each group of IsoP. The yield of extraction (supporting material Table 1) was calculated for each IsoP for two concentrations 
comparing the quantity recovered in presence of plasma to the native one. The yield ranged from 52.0% to 85.3% for low concentration and from 
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40.5% to 69.2% for high concentration. Surprisingly the yield extraction of F3t-IsoPs was above 100%, and no interference signal was observed 
for the non-spiked plasma extract; the reason for this observation is unknown.    
 
3.3.2 Performance of the method 
Repeatability and precision were then evaluated for intra- and inter-day at 3 concentrations: 3.91, 31.25 and 250 ng/mL (supporting material 
Table 2) were performed in triplicate. The intra-day accuracy ranged from 81.73% to 114.21% for all IsoP evaluated. The RSD values for 3 
injections were ≤ 8%. The inter-day variations were assessed by re-analyzing the samples every 15 days (n=2). The accuracies obtained were 
between 80.9% and 115.53% with a precision ≤ 15%. These data indicate that the method is highly reproducible for the 20 IsoP compounds 
analyzed. 
 
3.4 Application on various biological samples 
Our extraction and LC-MS/MS methods were applied to quantify non-enzymatic oxidized lipids from PUFAs in different biological samples. 
The different samples (Table 4) measured include human plasma and CSF, mice plasma, urine, liver, brain and muscle tissues A typical profile 
for human plasma is displayed in Figure 5. The structural matrix was taken into account for the quantity used for each type of samples and the 
size is shown in Table 4. Apart from CSF, IsoPs were detected and it appears to vary depending on the type of sample. No IsoPs were found in 
CSF, and it likely due to small volume used and concentration maybe below our limit of detection.  
The method developed was also used to perform the isoprostanoids profiles in the liver and brain of LDLR
-/-
 mice and to investigate if DHA 
supplementation could affect the profiles. The overall levels i.e. total summation of all the related isomers measured for F2-IsoPs (19 pg/mg vs 14 
pg/mg) and for F4-NeuroPs (19 pg/mg vs 17 pg/mg) in the liver and brain of control mice (white bars, Figures 6A and 6C) were slightly higher in 
the liver than the brain (+36% for F2-IsoP and +11% for F4-NeuroP). Furthermore, the total levels of F4-NeuroPs in the control mice liver and 
brain were similar to the levels of F2-IsoPs even though the concentration of DHA was 6 times and 34 times higher than AA in the liver and brain 
respectively (data not shown). Our observation suggest that the presence of high DHA concentration may contribute in protecting the liver and 
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brain from ROS attack despite it being more prone to peroxidation due to extra double bonds in the structure compared to AA [8]. When looking 
at the different isomers of the isoprostanoids (Figure 6B and 6D), it is interesting to note that the distribution of the different F2-IsoP isomers is 
slightly different in the liver and brain of the control mice with 15-epi-F2t-IsoP and 15-F2t-IsoP being more abundant in the brain; for the liver, 
the abundance of the different F2-isomers was as follows: 15-F2t<5-Epi-F2t>15-Epi-F2t>5-F2t.  
Among the F4-NeuroPs, the most abundant isomer was 4(RS)-4-F4t-NeuroP regardless of the tissue type. This finding is consistent with previous 
analysis performed in rat brain and heart tissues[34] .When the mice were supplemented with DHA (Figure 6, dark bars), the total level of F2-
IsoPs decreased in the brain (-40% for the sum of F2-IsoP) and the liver (-57% for the sum of F2-IsoP) whereas the total level of F4-NeuroPs 
increased by 51% in the brain and 247% in the liver. The concomitant decrease of F2-IsoPs and increase of F4-NeuroPs could be attributed at 
least in part by the replacement of AA by DHA in the membrane phospholipids. It should nevertheless be noted that the modulation of 
isoprostanoids profiles is much more pronounced in the liver than in the brain emphasizing the high “plasticity” of liver towards DHA 
supplementation. Consistently, correlations between levels of AA and F2-IsoP as well as DHA and F4-NeuroP were strong in the liver (R
2
=0.71 
and 0.96 respectively, Figure 7A and B) whereas they were much weaker in the brain (R
2
=0.02 and 0.16 respectively, data not shown).  
It should be noted in this report that we profiled the isoprostanoids in the liver and brain of an atherosclerotic mice and not normal mice. It is also 
anticipated that the profile of a normal mice may be different from our observation. Regardless, the objective of this study is to understand the 
differential changes between tissues. Our observation particularly displayed the importance of performing an integrated analysis of 
isoprostanoids levels since biological interpretation regarding tissue distribution and dietary modulation of lipid peroxidation is complex, and 
may lead to incorrect interpretation of experimental findings[10]. Moreover, the distribution of different types of isomers depends on the tissue 
type, which indicates the importance of tissue selection for studies evaluating bioactivity and organ crosstalk.  
In summary, we have described a LC-MS/MS methodology allowing simultaneous quantification of several isoprostanes derived from n-3 and n-
6 PUFA which are potential biomarkers in biological systems. Using the LC-MS/MS, we first characterized the analytical and quantification 
parameters of the 20 studied IsoPs and the 4 internal standards including LOD and LOQ concentration range. We optimized the sample 
preparation and the extraction process of these isoprostanoids which include Folch extraction, basic hydrolysis and SPE purification to obtain 
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low matrix effect and good yield of extraction. The method was validated on human plasma (repeatability and accuracy). The optimized 
chromatographic separation permits to separate nearly all the isomers in 30 minutes with a good sensitivity. We then applied this method to 
human samples (plasma and CSF) and mice samples (plasma, urine, liver, brain, muscle) to optimize the quantity required to be able to profile 
the isoprostanoids. Finally, the method was tested on brain and liver samples of LDLR
-/-
 mice with and without DHA supplementation to observe 
the change on the isoprostanoids profiles.  We found a variation in the distribution of different F2-IsoP isomers between tissues but not for F4-
NeuroP. DHA supplementation concomitantly increased F4-NeuroP levels.  OS is a key feature in a number of human diseases, since ROS are 
likely to be involved in all disease stages. Many of these diseases are associated to PUFA therefore it is important to identify and evaluate the 
IsoP compounds simultaneously, not only as reliable biomarkers but also for its functional roles in the PUFA metabolism; we believe that the 
information we obtained from such profiling will allow us to understand the interaction of the compounds in diet and disease studies. 
 
4. Conclusion 
 In this report, we developed a quick and robust method to determine multiple numbers of non-enzymatic oxidized lipid products of 
PUFAs, namely isoprostanoids in various biological sample in particular human plasma by LC-MS/MS. Unlike other reports, we were able to 
measure and incorporate new isoprostanoids from AdA and ALA as well as some isomers of AA, DHA and EPA into our method. However, it 
should be noted that not all 20 of the products determined were found in all biological samples therefore care must be taken when selecting them 
in metabolism studies. 
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Figure legends 
 
Figure 1. Chemical structure of isoprostanes derived from non-enzymatic oxidation of  n-6 PUFA, adrenic acid (AdA) and arachidonic acid 
(AA), and n-3 PUFA, -linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) measured in this study. 
 
Figure 2. Total ion current chromatogram of IsoP: with PA derivatization (A), with HP derivatization (B), and without derivatization (C) of the 
same sample mix. 
 
Figure 3. Chromatogram of selected reaction monitoring (SRM) of metabolites from each PUFA A: adrenic acid, B: arachidonic acid, C: -
linolenic acid, D: eicosapentaenoic acid and E: docosahexaenoic acid. The numbers indicated for each molecule refers to the compounds 
annotated in Table 1.  
 
Figure 4. Optimum chromatographic separation of diastereoisomers for 8-F3t-IsoP (a) and 8-epi-8-F3t-IsoP (b). The diastereoisomers of 5-F2t-
IsoP (c) and 5-epi-5-F2t-IsoP (d) were unable to resolve as well in the chromatographic analysis. 
 
Figure 5. Chromatogram of selected reaction monitoring (SRM) of metabolites detected in human plasma : 15-F2t-IsoP, 15-epi-15-F2t-IsoP (A) ; 
5-F2t-IsoP, 5-epi-5-F2t-IsoP (B) ; 10-F4t-NeuroP, 10-epi-10-F4t-NeuroP (C) ; 4(RS)-F4t-NeuroP (D) ; internal standard d4-15-F2t-IsoP (E). 
 
Figure 6. Isoprostanoids levels in the liver and brain of LDLR
-/-
 mice given either oleic acid rich sunflower oil (Ctrl, n=3) or a mixture of oleic 
acid rich sunflower oil and DHA rich tuna oil providing 2% of energy as DHA (DHA, n=3). The sum of F2-IsoPs and sum of F4-NeuroPs 
represents the ‘total’ sum of the isomers measured for the respective group. 
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Figure 7. Correlations between the levels of AA or DHA and the corresponding isoprostanoids (i.e. sum of F2-IsoPs and sum of F4-NeuroPs) in 
the liver (A and B).  
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Table 1. Selected reaction monitoring (SRM) of the isoprostanes  derived from polyunsaturated fatty acids. 
Compounds 
 
RT 
(min) 
Precursor 
ion 
(m/z) 
Product 
ion 
(m/z) 
F (V) 
 
CE (V) 
 
Adrenic acid      
Ent-7(RS)-7-F2t-dihomo-IsoP 
20.76 381 143 120 18 
17(RS)-F2t-dihomo-IsoP 20.90 381 337 120 12 
 
Arachidonic acid  
     
15-epi-15-F2t-IsoP 14.24 353 193 120 20 
15-F2t-IsoP 14.69 353 193 120 20 
5-F2t-IsoP 15.85 353 115 120 12 
5-epi-5-F2t-IsoP 16.01 353 115 120 12 
2,3-dinor-15-F2t-IsoP 8.29 325 237 100 5 
Ent-15(RS)-2,3-dinor-5,6-dihydro- 
15-F2t-IsoP 
 8.30 327 283 120 20 
      
d4-15-F2t-IsoP 14.61 357 197 120 20 
C21-15-F2t-IsoP 18.97 368 193 120 22 
      
alpha-Linolenic acid       
Ent-16-epi-16-F1t-PhytoP 6.66 327 283 120 15 
Ent-16-F1t-PhytoP 6.94 327 283 120 15 
9-F1t-PhytoP 7.30 327 283 120 15 
9-epi-9-F1t-PhytoP 7.58 327 283 120 15 
      
Eicosapentaenoic acid       
8-F3t-IsoP 10.70 351 127 120 18 
8-epi-8-F3t-IsoP 11.82 351 127 120 18 
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5-F3t-IsoP 11.48 351 115 120 15 
5-epi-5-F3t-IsoP 11.72 351 115 120 15 
      
Docosahexaenoic acid      
10-F4t-NeuroP 16.43 377 153 120 15 
10-epi-10-F4t-NeuroP 17.31 377 153 120 15 
4(RS)-F4t-NeuroP 19.50 377 101 120 15 
      
d4-10-epi-10-F4t-NeuroP                                          17.19 381 157 120 15 
d4-10-F4t-NeuroP 16.31 381 157 120 15 
d4-4(RS)-4-F4t-NeuroP 20.90 382 239 120 15 
The deuterated form of IsoP and NeuroP, and C21-15-F2t isoP were used as internal standards for quantification of samples in this study. IsoP: 
isoprostane; NeuroP: neuroprostane; F: Fragmentor; CE: collision energy; N : number.  
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Table 2. Selected reaction monitoring (SRM) of the derivatized  isoprostanes derived from polyunsaturated fatty acids.  
Compound 
 RT (min) 
Precursor ion  
(m/z) 
Product ion  
(m/z) 
F 
 (V) 
CE 
 (V) 
Adrenic acid 
Ent-7(RS)-7-F2t-dihomo-IsoP 24.17 455 109 130 30 
17(RS)-F2t-dihomo-IsoP 23.41 455 109 130 30 
 
Arachidonic acid 
15-epi-15-F2t-IsoP 14.73 427 109 120 25 
15-F2t-IsoP 15.34 427 109 120 25 
5-F2t-IsoP 18.32 427 109 120 30 
5-epi-5-F2t-IsoP 18.50 427 109 120 30 
Ent-15(RS)-2,3-dinor-5,6-dihydro-15-F2t-IsoP 8.89 401 109 120 30 
 
d4-15-F2t-IsoP 15.26 431 109 120 25 
C21-15-F2t-IsoP 20.83 442 109 120 20 
 
alpha-Linolenic acid       
Ent-16-epi-16-F1t-PhytoP 5.97 401 109 120 30 
Ent-16-F1t-PhytoP 6.21 401 109 120 30 
9-F1t-PhytoP 6.62 401 109 120 30 
9-epi-9-F1t-PhytoP 6.86 401 109 120 30 
      
Eicosapentaenoic acid       
8-F3t-IsoP 10.58 425 109 120 35 
8-epi-8-F3t-IsoP 11.91 425 109 120 35 
5-F3t-IsoP 12.77 425 109 130 30 
5-epi-5-F3t-IsoP 13.03 425 109 130 30 
      
Docosahexaenoic acid      
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10-F4t-NeuroP 16.80 451 109 120 20 
10-epi-10-F4t-NeuroP 18.17 451 109 120 20 
14(RS)-14-F4t-NeuroP 18.53 451 109 130 25 
4(RS)-F4t-NeuroP 23.81 451 109 130 25 
      
d4-10-epi-10-F4t-NeuroP                                          16.64 455 109 
 
120 20 
d4-10-F4t-NeuroP 18.04 455 109 120 20 
d4-4(RS)-4-F4t-NeuroP 23.90 455 109 140 30 
The deuterated form of IsoP and NeuroP, and C21-15-F2t isoP were used as internal standards for quantification of samples in this study. IsoP: 
isoprostane; NeuroP: neuroprostane; isofurane ; F: Fragmentor; CE: collision energy. 
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Table 3. Limit of detection (LOD) and limit of quantification (LOQ) of the pure compounds analyzed. 
 
Compound Linear regression R
2
 LOD 
(ng/mL) 
LOQ (ng/mL) IS 
Adrenic acid      
Ent-7(RS)-7-F2t-
dihomo-IsoP 
y = 0.0044 x - 0.0339 0.998 1.95 3.91 d4-15-F2t isoP 
17(RS)-F2t-
dihomo-IsoP 
y = 0.0065 x - 0.0639 0.998 7.81 15.63 d4-15-F2t isoP 
 
Arachidonic acid 
     
2,3-dinor-15-F2t-
IsoP 
y = 0.0079 x - 0.0558 0.998 0.98 1.95 d4-15-F2t isoP 
Ent-15(RS)-2,3-
dinor-5,6-dihydro-
15-F2t-IsoP 
y = 0.0079 x - 0.0747 0.998 3.91 7.81 d4-15-F2t isoP 
15-epi-15-F2t-IsoP 
y = 0.0024 x - 0.0183 0.998 1.95 3.91 d4-15-F2t isoP 
15-F2t-IsoP 
y = 0.0027 x - 0.0208 0.998 1.95 3.91 d4-15-F2t isoP 
5-F2t-IsoP 
y = 0.0032 x  - 0.0240 0.998 1.95 3.91 d4-15-F2t isoP 
5-epi-5-F2t-IsoP 
y = 0.0042 x - 0.0348 0.998 1.95 3.91 d4-15-F2t isoP 
 
Alpha-Linolenic 
acid 
     
Ent-16-epi-16-F1t-
PhytoP 
y = 0.0136 x - 0.1393 0.998 1.95 3.91 d4-15-F2t isoP 
Ent-16-F1t-PhytoP y = 0.0133 x - 0.1109 0.998 1.95 3.91 d4-15-F2t isoP 
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9-F1t-PhytoP y = 0.0166 x - 0.1316 0.998 1.95 3.91 d4-15-F2t isoP 
9-epi-9-F1t-PhytoP y = 0.0160 x – 0.1293 0.998 1.95 3.91 d4-15-F2t isoP 
Eicosapentaenoic acid     
8-F3t-IsoP 
y = 0.0042 x - 0.0314 0.998 0.98 1.95 d4-15-F2t isoP 
8-epi-8-F3t-IsoP 
y = 0.0035 x - 0.0299 0.998 0.98 1.95 d4-15-F2t isoP 
5-F3t-IsoP 
y = 0.0018 x - 0.0186 0.998 3.91 7.81 d4-15-F2t isoP 
5-epi-5-F3t-IsoP y = 0.0012 x - 0.0111 0.998 3.91 7.81 d4-15-F2t isoP 
Docosahexaenoic acid     
10-F4t-NeuroP 
y = 0.0017 x - 0.0117 0.998 0.49 0.98 d4-10-F4t-
NeuroP 
10-epi-10-F4t-
NeuroP 
y = 0.0023 x - 0.0162 0.998 0.98 1.95 d4-10-epi-10-
F4t-NeuroP 
14(RS)-14-F4t-
NeuroP 
y = 6.2450.10
-5
 x - 6.7300.10
-4
 0.998 15.63 31.25 d4-10-epi-10-
F4t-NeuroP 
 
 
4(RS)-F4t-NeuroP 
y = 1.8386.10
-4
 x - 0.0019 0.998 7.81 15.63 d4-4(RS)-F4t-
NeuroP 
The deuterated form of IsoP and NeuroP were used as internal standards to determine the LOD and LOQ of the analytes. IsoP: isoprostane; 
NeuroP: neuroprostane. 
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Table 4. Types of isoprostanes quantified in human and mice biological samples using the 
method described in Section 3. 
 
Biological samples Sample size IsoPs detected 
Human plasma 1 mL 15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, 5-
epi-5-F2t-IsoP, 10-F4t-NeuroP, 10-epi-10-F4t-
NeuroP, 4(RS)-F4t-NeuroP 
 
Human CSF 
 
600 µL n.d 
Mouse Plasma   200 µL 15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, 5-
epi-5-F2t-IsoP 
 
Mouse Urine  200 µL Ent 15 (RS) 2,3 dinor 5,6 dihydro 15-F2t-isoP,  
15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, 5-
epi-5-F2t-IsoP 
 
Mouse Liver 200 mg 15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, 5-
epi-5-F2t-IsoP, 10-F4t-NeuroP, 10-epi-10-F4t-
NeuroP, 4(RS)-F4t-NeuroP 
 
Mouse Brain 200 mg 15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, 5-
epi-5-F2t-IsoP, 10-F4t-NeuroP, 10-epi-10-F4t-
NeuroP, 4(RS)-F4t-NeuroP, Ent-7(RS)-F2t-
Dihomo IsoP 
 
Mouse Muscle 
 
200 mg 5-F2t-IsoP, 5-epi-5-F2t-IsoP 
n.d. not detected; IsoP: isoprostane; NeuroP: neuroprostane 
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Supporting material Table 1.  
Plasma matrix effect and extraction efficiency of healthy human plasma.  
Compound name Matrix effect Yield extraction 
250 ng/mL 31.25 ng/mL 250 ng/mL 31.25 ng/mL 
Adrenic acid     
Ent-7(RS)-F2t-dihomo 
IsoP 
66.8 ± 9.6 63.1 ± 8.2 63.2 ± 2.3 77.6 ± 1.2 
17(RS)-F2t-dihomo IsoP 68.2 ± 9.2 69.1 ± 8.4 62.9 ± 2.8 83.9 ± 2.5 
     
Arachidonic acid     
15-epi-15-F2t-IsoP 70.5 ± 9.2 74.1 ± 7.7 58.9 ± 2.5 73.2 ± 2.0 
15-F2t-IsoP 68.6 ± 9.7 73.2 ± 9.0 59.6 ± 2.0 69.9 ± 2.3 
5-F2t-IsoP 64.7 ±10.7 82.1 ± 7.6 61.3 ± 2.6 62.4 ± 10.5 
5-epi-5-F2t-IsoP 69.2 ± 9.5 64.9 ± 10.3 58.0 ± 3.0 72.3 ± 8.0 
2,3-dinor-15-F2t-IsoP 59.6 ± 8.2 57.0 ± 6.9 51.6 ± 0.9 71.1 ± 11.6 
Ent-15(RS)-2,3-dinor-
5,6-dihydro-15-F2t-IsoP 
 
62.5 ± 9.3 73.6 ± 2.4 57.9 ± 0.9 79.1 ± 5.5 
     
d4-15-F2t-IsoP 67.1 ± 8.8 69.8 ± 8.6 
C21-15-F2t-IsoP 61.2 ± 8.6 79.2 ± 9.9 
     
Alpha-Linolenic acid     
Ent-16-epi-F1t-PhytoP 58.0 ± 8.7 53.5 ± 6.1 40.5 ± 2.1 58.3 ± 5.7 
Ent-16-F1t-PhytoP 58.7 ± 8.6 53.8 ± 6.4 42.7 ± 1.6 60.4 ± 3.2 
9-F1t-PhytoP 56.7 ± 8.5 53.7 ± 5.5 46.7 ± 1.7 65.2 ± 7.3 
9-epi-9-F1t-PhytoP 
 
59.1 ± 8.9 51.8 ± 6.4 45.0 ± 1.2 67.1 ± 7.6 
     
Eicosapentaenoic acid     
8-F3t-IsoP 65.5 ± 8.8 57.8 ± 8.2 54.0 ± 2.1 74.2 ± 4.9 
8-epi-8-F3t-IsoP 64.5 ± 8.9 62.1 ± 6.2 55.5 ± 2.4 65.5 ± 3.4 
5-F3t-IsoP 59.9 ± 8.0 65.1 ± 6.4 104.9  ± 4.3 117.9  ± 5.8 
5-epi-5-F3t-IsoP 
 
64.7 ± 7.7 68.2 ± 8.9 112.0  ± 6.4 131.8  ± 0.6 
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Docosahexaenoic acid     
10-F4t-NeuroP 75.3 ± 9.7 68.2 ± 9.8 54.9 ± 2.5 74.0 ± 5.4 
10-epi-10-F4t-NeuroP 72.5 ± 9.1 64.6 ± 8.4 55.7 ± 2.5 77.4 ± 0.1 
14(RS)-14-F4t-NeuroP 77.3 ± 8.1 82.6 ± 7.1 58.9 ± 4.8 52.0 ± 10.6 
4(RS)-F4t-NeuroP 73.1 ± 11.1 92.7 ± 4.0 61.0 ± 3.9 76.6 ± 0.1 
     
d4-10-epi-10-F4t-NeuroP                                        66.2 ± 4.1 72.5 ± 7.2 
d4-10-F4t-NeuroP 73.5 ± 4.7 68.1 ± 7.6 
d4-4(RS)-F4t-NeuroP 64.8 ± 12.1 63.8 ± 7.4 
The matrix and extraction yield were tested by the addition of low and high concentration of 
the respective compounds as described in Section 2. IsoP: isoprostane; NeuroP: 
neuroprostane. 
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Supporting material Table 2 
Repeatability and accuracy of the method for isoprostanes evaluation in human plasma. 
Compound Nominal conc. 
(ng/mL) 
Intraday Interday 
Measured RSD % Accuracy % Measured RSD % Accuracy % 
Adrenic acid        
Ent-7(RS)-F2t-
dihomo-IsoP 
 
 
3.91 
31.25 
250 
3.91 ± 0.28 
31.31 ± 0.37  
256.91 ±1.65 
0.32 
0.24 
0.17 
102.28 
101.53 
102.77 
4.48 ± 0.81 
33.79 ± 0.67  
273.58 ± 4.50 
18.04 
1.97 
1.65 
114.61 
82.35 
111.12 
17(RS)-F2t-dihomo-
IsoP 
 
 
3.91 
31.25 
250 
n.d  
31.24 ± 1.77  
253.60 ±0.53 
n.d  
0.16 
0.11 
n.d  
96.37 
101.44 
n.d  
26.41 ± 0.83  
262.76 ± 7.84 
n.d  
3.13 
2.98 
n.d  
84.43 
105.10 
        
Arachidonic acid        
15-epi-15-F2t-IsoP 
 
 
3.91 
31.25 
250 
3.96 ± 0.54 
31.57 ± 1.04 
254.41 ± 1.72 
0.52 
0.42 
0.30 
108.20 
97.39 
101.77 
4.50 ± 0.18 
33.44 ± 0.50 
269.80 ± 10.52 
4.02 
1.50 
3.90 
115.29 
86.94 
104.69 
15-F2t-IsoP 
 
 
3.91 
31.25 
250 
4.10 ± 0.27 
30.94 ± 1.44 
257.20 ± 4.92 
0.47 
0.38 
0.27 
108.82 
100.42 
102.88 
4.21 ± 0.59 
32.60 ± 0.45 
275.25 ± 5.98 
13.98 
1.39 
2.17 
107.85 
84.51 
106.05 
5-F2t-IsoP 
 
 
3.91 
31.25 
3.64 ± 0.02 
31.48 ± 0.60  
0.49 
0.33 
93.26 
99.68 
4.14 ± 0.37 
30.02 ± 0.97  
8.91 
3.22 
105.95 
88.39 
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250 260.76 ±1.08 0.23 104.30 268.06 ± 3.60 1.34 107.19 
5-epi-5-F2t-IsoP 
 
 
3.91 
31.25 
250 
3.71 ± 0.13 
31.41 ± 0.86  
254.45 ±5.61 
0.35 
0.26 
0.17 
93.84 
102.67 
101.78 
3.79 ± 0.41 
32.24 ± 0.30  
271.10 ± 4.77 
0.71 
0.92 
1.76 
91.19 
80.90 
108.36 
2,3-dinor-15-F2t-IsoP 
 
 
 
3.91 
31.25 
250 
3.50 ± 0.11 
31.39 ± 0.20 
253.89 ± 1.57 
3.09 
0.62 
0.62 
87.01 
100.34 
101.56 
4.14 ± 0.52 
30.06 ± 0.49  
245.48 ± 8.11 
12.56 
1.64 
3.30 
105.99 
84.98 
98.61 
Ent-15 -(RS)-2,3-
dinor 5,6 dihydro-
15-F2t-IsoP 
 
 
3.91 
31.25 
250 
3.97 ± 0.32 
31.27 ± 0.71 
254.19 ± 1.94 
8.05 
2.27 
0.09 
110.80 
99.21 
101.67 
4.80 ± 0.41 
33.17 ± 1.22  
237.99 ± 9.28 
8.44 
3.68 
3.90 
115.53 
92.75 
96.48 
        
Alpha-Linolenic acid        
Ent-16-epi-16-F1t-
PhytoP 
3.91 
31.25 
250 
3.37 ± 0.25 
31.39 ± 0.27 
252.93 ± 2.70 
7.49 
0.86 
1.07 
81.73 
100.26 
101.17 
4.04 ± 0.19 
32.84 ± 0.55  
251.57 ± 7.61 
4.63 
1.68 
3.02 
103.49 
87.89 
100.06 
Ent-16-F1t-PhytoP 3.91 
31.25 
250 
3.66 ± 0.18 
31.43 ± 0.22 
254.35 ± 2.88 
4.93 
0.70 
1.13 
95.35 
100.12 
101.74 
3.94 ± 0.10 
31.82 ± 0.92  
246.90 ± 9.44 
2.56 
2.88 
3.82 
100.96 
87.51 
98.89 
9-F1t-PhytoP 3.91 
31.25 
250 
3.64 ± 0.09 
31.31 ± 0.04 
257.24 ± 3.60 
2.38 
0.13 
1.40 
90.53 
100.18 
102.90 
4.24 ± 0.02 
32.04 ± 0.87  
256.15 ± 8.56 
0.47 
2.71 
3.34 
108.65 
85.74 
101.28 
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9-epi-9-F1t-PhytoP 3.91 
31.25 
250 
3.57 ± 0.02 
31.31 ± 0.58 
256.35 ± 2.21 
0.61 
1.87 
0.86 
91.37 
99.36 
102.54 
4.44 ± 0.28 
31.25 ± 0.84  
253.11 ± 7.69 
6.22 
2.70 
3.04 
113.55 
85.27 
100.54 
        
Eicosapentaenoic acid       
8-F3t-IsoP 
 
 
3.91 
31.25 
250 
3.48 ± 0.14 
31.15 ± 0.61 
253.18 ± 1.67 
3.92 
1.96 
0.17 
89.71 
100.59 
101.27 
4.06 ± 0.77 
32.05 ± 0.69  
243.29 ± 8.38 
18.90 
2.16 
3.45 
103.87 
88.59 
97.93 
8-epi-8-F3t-IsoP 
 
 
3.91 
31.25 
250 
3.57 ± 0.13 
31.48 ± 0.85 
252.98 ± 3.52 
0.41 
0.31 
0.21 
94.08 
97.61 
101.19 
4.42 ± 0.29 
32.55 ± 1.19  
243.60 ± 4.45 
6.53 
3.66 
1.83 
113.12 
89.77 
97.99 
5-F3t-IsoP 
 
 
3.91 
31.25 
250 
3.85 ± 0.61 
31.02 ± 0.59 
254.47 ± 4.08 
0.86 
0.59 
0.40 
86.07 
99.26 
101.79 
3.60 ± 0.26 
30.36 ± 1.21 
226.63 ± 5.18 
7.17 
3.97 
2.29 
92.08 
89.52 
93.51 
5-epi-5-F3t-IsoP 
 
 
3.91 
31.25 
250 
3.75 ± 0.54 
31.19 ± 1.11 
254.04 ± 4.84 
1.48 
0.86 
0.61 
85.89 
102.31 
101.62 
3.95 ± 0.26 
30.20 ± 1.82 
232.31 ± 8.13 
6.57 
6.01 
3.50 
101.03 
88.80 
95.10 
Docosahexaenoic acid       
10-F4t-NeuroP 
 
 
3.91 
31.25 
250 
3.47 ± 0.20 
31.27 ± 0.96  
256.74 ± 1.01 
0.19 
0.16 
0.10 
93.71 
103.17 
102.70 
3.76 ± 0.11 
32.18 ± 0.37 
259.93 ± 3.98 
2.81 
1.16 
1.53 
96.17 
85.61 
102.25 
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Three nominal concentrations of the compounds were used to assess the stability of the compounds within the day (intraday) and between 15 
days intervals (interday). IsoP: isoprostane; NeuroP: neuroprostane; IsoF: isofuran.
10-epi-10-F4t-NeuroP 
 
 
3.91 
31.25 
250 
3.75 ± 0.16 
31.29 ± 0.16  
256.15 ± 3.60 
0.22 
0.17 
0.12 
95.14 
99.53 
102.46 
3.94 ± 0.47 
31.72 ± 0.70 
262.56 ± 1.97 
11.83 
2.22 
0.75 
100.92 
84.31 
102.93 
14(RS)-14-F4t-
NeuroP 
 
 
3.91 
31.25 
250 
n.d  
33.66 ± 0.83  
255.05 ± 9.44 
n.d  
5.49 
4.32 
n.d  
109.19 
102.02 
n.d  
29.42 ± 2.84  
258.99 ± 16.26 
n.d  
9.66 
6.25 
n.d  
94.15 
97.67 
4(RS)-F4t-NeuroP 
 
 
3.91 
31.25 
250 
n.d  
31.41 ± 2.40  
256.93 ± 3.24 
n.d  
2.03 
1.46 
n.d  
101.15 
102.77 
n.d  
35.16 ± 3.18  
261.07 ± 3.00 
n.d  
9.04 
1.15 
n.d  
93.60 
102.47 
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DPDS : 2,2’-dipyridyl disulfide 
AGTA : Ethylene glycol tetra acetic acid 
EPA : Eicosapentaenoic acid 
ESI : Electrospray ionization 
HP : 2-hydrazinopyridine 
HPLC : High-pressure liquid chromatography 
IsoPs : Isoprostanes 
LOD : limit of detection 
LOQ : limit of quantification 
m/z : Mass-to-charge ratio 
MRM : Multiple reaction monitoring 
MS : Mass spectrometry 
NeuroPs : Neuroprostanes 
OS : Oxidative Stress 
PhytoPs : Phytoprostanes 
PA : 2-picolylamine 
PUFAs : Polyunsaturated fatty acids 
ROS : Reactive oxygen species 
SPE : Solid-phase extraction 
SRM : Selected-reaction monitoring 
S/N : signal to noise ratio  
TPP : Triphenylphosphine 
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Abstract 
Isoprostanoids are a group of non-enzymatic oxygenated metabolites of polyunsaturated fatty acids. It belongs to oxylipins group, which are 
important lipid mediators in biological processes, such as tissue repair, blood clotting, blood vessel permeability, inflammation and immunity 
regulation. Recently, isoprostanoids from eicosapentaenoic, docosahexaenoic, adrenic and -linolenic namely F3-isoprostanes, F4-
neuroprostanes, F2-dihomo-isoprostanes and F1-phytoprostanes, respectively have attracted attention because of their putative contribution to 
health. Since isoprostanoids are derived from different substrate of PUFAs and can have similar or opposing biological consequences, a total 
isoprostanoids profile is essential to understand the overall effect in the testing model. However, the concentration of most isoprostanoids range 
from picogram to nanogram, therefore a sensitive method to quantify 20 isoprostanoids simultaneously was formulated and measured by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). The lipid portion from various biological samples was extracted prior to LC-MS/MS 
evaluation. For all the isoprostanoids LOD and LOQ, and the method was validated on plasma samples for matrix effect, yield of extraction and 
reproducibility were determined. The methodology was further tested for the isoprostanoids profiles in brain and liver of LDLR
-/-
 mice with and 
without docosahexaenoic acid (DHA) supplementation. Our analysis showed similar levels of total F2-isoprostanes and F4-neuroprostanes in the 
liver and brain of non-supplemented LDLR
-/-
 mice. The distribution of different F2-isoprostane isomers varied between tissues but not for F4-
neuroprostanes which were predominated by the 4(RS)-4-F4t-neuroprostane isomer. DHA supplementation to LDLR
-/-
 mice concomitantly 
increased total F4-neuroprostanes levels compared to F2-isoprostanes but this effect was more pronounced in the liver than brain.  
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1. Introduction  
Excessive free radicals in vivo have been implicated in a number of human diseases such as neurodegenerative, cardiovascular, pulmonary disorder and 
cancer[1] [2]. The most common free radicals are reactive oxygen species (ROS), which can modify lipids, proteins and nucleic acids. Of the lipids in 
particular, the polyunsaturated fatty acids (PUFA) form a wide variety of oxygenated metabolites [3] [4]. Among them, the isoprostanes (IsoPs) 
appears to be a promising group of biomarkers to be assessed for oxidative stress (OS) assessment in vivo for over two decades due to its specificity and 
sensitivity[5] [6]. These compounds are formed in situ on membrane phospholipids and then released into their free form via phospholipase A2 and 
platelet activating factor hydrolase for circulation. Elevation of IsoPs, in particular those originated from arachidonic acid (AA, 20:4 n-6) also 
known as F2-IsoPs in biological fluids (e.g. plasma and urines) are recognized as the reference biomarker for lipid peroxidation and OS in most 
biological systems. Beyond their capacity of OS as biomarker, IsoPs from n-3 PUFA also demonstrated to be biologically active[7] [8] [9]. 
Therefore it is crucial to be able to quantify the different isoforms in a large panel of biological samples to integrate this chemical and biological 
complexity.  
Unlike PUFAs, the isoprostanoids are quite complex to assess since the concentration range is very low (from picogram to nanogram) in most 
biological samples. Moreover, depending on the parent PUFAs, a large diversity of molecule has been discovered as shown in Figure 1. Analysis 
of these metabolites in biological samples is a challenge and depends on the robustness of the analytical instrumentation. Further, it requires one 
or several preparation steps, including hydrolysis and extraction from their biological matrix before analysis by radio immunological methods 
(RIA) or gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS), which are often coupled to 
another mass spectrometer (MS/MS) to increase the sensitivity[10]. It is well known to analysts, that RIA is not specific enough to provide 
efficient quantification of different IsoPs [11] To date, LC-MS/MS is the most common technique to quantify these biomarkers [12], even if the 
mass spectrometry is not the perfect method to perform absolute quantification compared to GC-MS because of the various ionization efficiency 
between different molecules. These changes can be very important when comparing compounds with very close structures especially for lipids 
including the IsoPs. In order to optimize ionization efficacy for each compound, it is essential to have the pure standard to develop a rigorous 
quantitative method. Although some standards are available commercially, many of the novel ones are unavailable. Through total synthesis, 
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Durand’s group was able to synthesize [13-21] these novel standards, for example dihomo-IsoPs from adrenic acid (C22:4 n-6, AdA) for mass 
spectrometry analysis.  
In this study, we developed a complete quantitative profiling of IsoPs by LC-MS/MS. As IsoPs are present in a very low concentration it was 
imperative to improve largely the sensitivity of the method therefore we also tried two different derivatization procedures of the carboxylic acid 
function to improve the ionization of molecules. For both profiles, with and without derivatization, chromatographic separation has been 
optimized and sensitivity compared. The two methods have been tested on human plasma and the best one was applied in this study. The final 
methodology was then validated on plasma sample and applied to other biological samples, namely cerebrospinal fluid (CSF), urine, and brain, 
liver and muscle tissues. Our methodology was finally checked on a mouse model, in which the goal was to determine the isoprostanoids 
profiling in the brain and liver of LDLR
-/-
 mice and to investigate the effect of docosahexaenoic acid (C22:6 n-3, DHA) supplementation on these 
profiles.  
 
2. Material and methods 
2.1. Chemicals 
Commercially available IsoP standards (d4-15-F2t-IsoP and 2,3-dinor-15-F2t-IsoP) were purchased from Cayman Chemicals (Ann Arbor, MI, 
USA). Others standards Ent-16-epi-16-F1t-PhytoP, Ent-16-F1t-PhytoP, 9-F1t-PhytoP, 9-epi-9-F1t-PhytoP, Ent-15(RS)-2,3-dinor-5,6 dihydro-15-
F2t-IsoP, 8-F3t-IsoP, 8-epi-8-F3t-IsoP, 5-F3t-IsoP, 5-epi-5-F3t-IsoP, 15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, 5-epi-5-F2t-IsoP, 10-F4t-NeuroP, 
10-epi-10-F4t-NeuroP, 14(RS)-14-F4t-NeuroP, 4(RS)-4-F4t-NeuroP, Ent-7(RS)-7-F2t-dihomo-IsoP, 17(RS)-17-F2t-dihomo-IsoP, C21-15-F2t-IsoP, 
d4-10-epi-10-F4t-NeuroP, d4-10-F4t-NeuroP, d4-4(RS)-4-F4t-NeuroP were synthesized according to our published procedures
13 
.Hexane, ethanol 
absolute, acetic acid potassium hydroxide (KOH), methanol (MeOH; HPLC gradient Grade), butylated hydroxytoluene (BHT) and formic acid 
were purchased from Sigma Aldrich (Saint Quentin Fallavier, France). Acetonitrile (ACN; HPLC grade) was obtained from Acros Organics 
(Illkirch, France). Ammonia solution 30 % (NH4OH) was purchased from Carlo Erba Reagenti (Cornaredo, Italy). Water used in this study was 
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purified on a milliQ system (Millipore). The 96 well-plate for solid extraction (SPE) (Oasis Max, 60 mg) was purchased from Waters (Saint-
Quentin en Yvelines, France). 
 
2.2. Standards preparation for linearity and reproducibility assessment 
Standard solutions with or without derivatization were prepared in MeOH at the following concentrations, 0.06, 0.12, 0.24, 0.49, 0.98, 1.95, 3.91, 
7.81, 15.63, 31.25, 62.5, 125, 250, and 500 ng mL-1 for all primary standards. The concentration of the deuterated internal standards (IS) used 5 
ng taken from 250 ng mL-1 stock solution. Calibration curves were calculated by the area ratio of the analyte and the internal standard. The 
linearity and the accuracy of the detection were determined and the limit of detection (LOD : lower point with s/n > 5) and limit of quantification 
(LOQ: lower point with s/n > 10) were defined for the 20 compounds.  
 
2.3. Biological fluid extraction 
Healthy human plasma (1 mL) or CSF (600 L), LDLR-/- mice plasma (≥200 L) or urine (≥200 L) were collected, and supplemented with 
BHT (1% in ethanol), and stored at -80°C. For the extraction, the samples were thawed and spiked with 5 ng of each internal standard. A volume 
of 985 µL of hydrolysis solution (KOH 1M in MeOH) was added. The resulting mixture was mixed and incubated at 40°C for 30 minutes 
(excepted for urine). After cooling in room temperature, 2 mL of 40 mM formic acid (pH 4.5 adjusted with 1 M NaOH) was added. Thereafter, 
the samples including urine were cleaned and extracted by solid-phase extraction (SPE) on 96-well plate OASIS MAX 60 mg (Waters, USA) 
modified from Lee et al. method [22]. Briefly, the wells were cleaned with 2 mL of MeOH and conditioned with 2 mL of 40 mM formic acid (pH 
4.5). After loading the samples, the wells were washed with 2 mL of 2% NH4OH followed by 2 mL of MeOH/20 mM formic acid (20:80 v/v) 
and 2 mL of hexane. The IsoPs were eluted with 2 ml hexane/ethanol/acetic acid (70:29.4:0.6 v/v/v). After drying under nitrogen gas, the 
samples were re-dissolved with 20 µL of MeOH. A part of the sample (5 l) was taken for LC-MS/MS analysis and the remaining samples were 
derivatized prior to LC-MS/MS measurement. 
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2.4. Biological tissue preparation 
The tissue samples were stored at -80°C before preparation. To a total of 200 mg of thawed tissue (brain, liver or muscle) sample, 1 mL of Folch 
solution (CHCl3:MeOH, 2:1,  v/v) containing 10 µL BHT (1 % in ethanol) was added and spiked with 5 ng of each internal standard.  The 
mixture was homogenized with a Fast Prep instrument (MP Biomedicals) for 30 s at 6.5 m/s. Then the homogenized tissue was further extracted 
with 1.5 mL ice-cold Folch solution (CHCl3: MeOH, 2:1, v/v) and 0.5 mL of ultrapure water. The mix was shaken for 30 s and centrifuge for 10 
min at room temperature to separate the aqueous and organic layers. The lower organic layer was carefully removed and transferred to a pyrex 
tube and then evaporated under nitrogen gas. The extracted lipid was dissolved in 1 mL of hydrolysis solution (KOH 1M in MeOH) and 
incubated at 40°C for 30 minutes. After cooling in room temperature, 3 mL of 40 mM formic acid was added. The samples were then cleaned 
and extracted by SPE as described in section 2.3. 
 
2.5. Derivatization of the extracted samples 
To a set of extracted samples, 10 µL of freshly prepared solution of 10 mM triphenylphosphine (TPP), 10 mM 2,2’-dipridyl disulfide (DPDS) 
and 10 µg 2-picolyamine (PA) prepared separately in acetonitrile were added successively. To another set of the extracted samples, freshly 
prepared 10 µL of TPP and DPDS, and 10 µL of freshly prepared 10 µg 2-hydrazinopyridine (HP) in acetonitrile were added. The sample 
mixture was incubated at 60°C for 10 min. The mixture was dried under nitrogen and then reconstituted in MeOH for LC-MS/MS analysis.  
 
2.6. LC-MS/MS analysis 
High performance liquid chromatography (HPLC) was performed using an Agilent 1290 Infinity equipped with a thermostated autosampler, a 
binary pump and a column oven. The analytical column was a Zorbax SB-C18 Rapid Resolution HD (2,1 x 100 mm; 1,8 µm) (Agilent 
Technologies, USA) and maintained at 25°C. The mobile phases consisted of water: formic acid (99.9:0.1;v/v) (A) and acetonitrile : formic acid 
(99.9:0.1, v/v) (B). The linear gradient was set as follows for the non-derivatized IsoPs analysis: 20% B at 0 min, 30% B at 15 min, 35% B at 20 
min, 100% B at 23 min, 100% B at 26 min, and 20% B at 26.5 min for 1.5 min of equilibration. For the derivatized IsoPs, the gradient was set to 
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18% B at 0 min, 30% B at 22 min, 35% B at 26 min, 100% B at 28 min, 100% B at 29 min, and 18% B at 29.5 min for 1.5 min of equilibration. 
The flow rate was set at 0.3 mL/min. The autosampler was fixed at 5◦C and the injection volume was 5 µL per analysis. The HPLC system was 
coupled on-line to an Agilent 6460 triple quadrupole MS (Agilent Technologies, USA) equipped with electrospray ionization (ESI). The ESI was 
performed in negative ion mode for non-derivatized IsoPs and positive mode for derivatized IsoPs. The MS source parameters were set as 
follows: source temperature 325ºC, nebulizer gas (nitrogen) flow rate 10 L min-1, sheath gas temperature 350ºC, sheath gas (nitrogen) flow rate 
12 L min-1 and the spray voltage adjusted to −3000 V. The dwell time used was 10 ms. The analysis was performed in Selected Reaction 
Monitoring (SRM) detection mode using nitrogen as the collision gas. The SRM of each compound without (Table 1) or with derivatization 
(Table 2) were pre-determined by MS/MS analysis. Peak detection, integration and quantitative analysis were performed by Mass Hunter 
Quantitative analysis software (Agilent Technologies, USA). Concentration of the analytes was calculated by calibration curves obtained in 
Section 2.2.  
 
2.7. Accuracy and precision 
Repeatability and precision were respectively assessed using relative standard deviation (% RSD) and accuracy at 3 concentrations (3.91, 31.25 
and 250 ng mL-1) of pure standards in triplicate determination. The concentration was subsequently calculated using the standard curves 
generated. For inter-day variation, the samples were analyzed on 2 different days, with 15 days in between interval. 
 
2.8. Validation of sample preparation 
The preparation of human plasma sample was validated through the yield extraction and the matrix effect. Briefly, three sets in triplicate were 
prepared :  500 µL of plasma (n = 3) were spiked with 5 ng of IS stock solution and 2 different concentrations of standards (31.25 and 250 ng 
mL-1) and were extracted as described in Section 2.3: 1) 500 µL of plasma (n = 3) were extracted and then spiked with 5 ng of IS stock solution 
with 2 different concentrations of standards (31.25 and 250 ng mL-1), and 2) a separate set of pure 5 ng of IS stock solution and standards 
solutions (31.25 and 250 ng mL-1) in the absence of plasma extract were prepared in MeOH. All sets (of three samples) were analyzed in 
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triplicate using the LC-MS/MS. The yield extraction was determined as the percent difference between peak areas of standards in pre-spiked and 
post-spiked samples. The matrix effect was determined as the percentage difference between peak areas of standards added to the extracted 
samples and pure standard. The plasma matrix effect and yield extraction were calculated for each compound measured in the method described. 
 
2.9. Biological samples 
 
With permission, a sub-group of LDLR
-/-
 mice from a previous study [23] was used to determine the effect of DHA supplementation on the 
profile of the isoprostanoids in the brain and liver. Briefly, from 8 weeks of age and for 20 weeks, the mice received by daily oral gavages (50 
L, 5 days/week) either oleic acid rich sunflower oil (Lesieur, Asnières-sur-Seine, France; Control group) or a mixture of oleic acid rich 
sunflower oil and DHA rich tuna oil (OMEGAVIE DHA90TG, Polaris Nutritional Lipids, France containing 90% of DHA as TG) providing 2% 
(or 35.5 mg/d/mouse) of energy as DHA. At the end of the supplementation, the mice were anaesthetized (40 mg pentobarbital/kg body weight) 
and the tissue samples were rapidly removed and snap-frozen in liquid nitrogen and stored at -80°C until analysis. Quantification of DHA and 
AA were performed on brain and liver sample. In brief, after an organic extraction in presence of internal standard, the total fatty acid were 
methylated, analysed and quantified on a gas chromatography-flame ionization detector (GC-FID) system [24]. 
 
3. Results and discussion  
3.1 LC-MS/MS method development 
In order to achieve the necessary selectivity and sensitivity of the method, the mass detection and chromatographic separation of each standard 
with or without derivatization were individually optimized.  
3.1.1 Mass detection 
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IsoPs analyzed in this study have different structures comparatively. Nevertheless, due to their common carboxylic acid moiety, they were all 
detected in the negative ion mode as [M−H]− ions. Firstly, the fragmentor voltage was optimized for each compound in product ion scan mode. 
This parameter promotes the transmission of the ions between the ionization source and the first quadrupole. Low voltages lead to poor 
transmission efficiency whereas too high voltage values lead to excessive fragmentation. The optimum value corresponded to a maximum 
transmission of the [M−H]− ions without fragmentation. The second optimized parameter was the collision energy for each MS/MS transition to 
monitor; the most abundant one was selected. In this study, one specific fragment was selected for each compound and the collision energy was 
optimized for each SRM transition (Table 1). SRM transitions observed for this study are divided according to the PUFA type, that includes 15-
F2 series (m/z 353 to m/z 193), 5-F2 series (m/z 353 to m/z 115), 8-F3 series (m/z 351 to m/z 127), and 5-F3 series (m/z 351 to m/z 115) [25]. For 
the F1-PhytoP, the carboxylate portion was lost to give SRM m/z 327 to m/z 283, whereas 10-F4-NeuroP seems to fragment in the same way as 
8-F3 series (m/z 377 to m/z 153). For the remaining compounds, the fragmentations were not as definite. 
Since the concentration of the IsoPs is low in biological samples, analysts may opt for a derivatization procedure to increase the volatility and 
polarity of the compounds. To enhance the detection responses of carboxylic acids in ESI-MS/MS several chemical derivatization procedure can 
be applied and measured in the positive mode of the LC-MS/MS[26] [27]. However, the derivatization reagents are not always commercially 
available and the preparation can be long and time consuming. In our study, we tested two simple reagents 2-hydrazinopyridine (HP) and 2-
picolylamine (PA),  which can be derivatized in one step under mild conditions[28]. When the reagents react with the acidic function of the 
IsoPs, the HP and PA form a hydrazide and an amide bond, respectively. The sensitivity obtained was preferably for PA derivatives than HP 
derivatives (Figure 2), therefore MS parameters were optimized only for PA (Table 2). An important drawback of this derivatization method is 
that for all species a unique PA fragment of m/z = 109 is obtained, which creates poor specificity of the IsoP tested. 
 
3.1.2 Chromatographic separation 
The IsoP determined in this study have similar molecular mass and structure. As a result, the liquid chromatographic separation of each 
metabolite is a crucial step where each isomer of the IsoPs needs to be optimized to be separated in the chromatogram for detection.  In this 
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study, the eluent phase was acidic and a semi-linear gradient elution allows the chromatographic resolution of most compounds on a 10 cm C18 
reverse phase column within 30 minutes. The gradient was also designed for the measurement of PA derivatives. As shown in Figure 3, F1t-
PhytoPs eluted first, followed by 2,3-dinor-15-F2t-IsoP, F3t-IsoPs, F2t-IsoPs, then F4t-NeuroPs and F2t-dihomo-IsoPs. The isobaric compounds 
bearing the same transition such as F1t-PhytoPs were successfully separated (Table 1). Furthermore, all the isomers were resolved in the 
chromatographic separation including 8-F3t- and 8-epi-8-F3t-IsoPs (Figure 4A and B), while for 5-F2t- and 5-epi-5-F2t-IsoPs the separation 
between the two peaks showed an overlap at the tail of the chromatographic peak (Figure 4C and D). The separation was comparable with PA 
derivatives indicating derivatization procedure did not improve the separation. 
 
3.1.3 Sensitivity 
To quantify our isoprostanoids we first had to choose the appropriate internal internal standard for each metabolite. NeuroPs and 15-F2t-IsoP 
were quantified through their deuterated equivalent and for other IsoPs, d4-15-F2t-IsoP and C21-15-F2t-IsoP were used.  Based on the internal 
standard, each calibration curve was obtained with 10 concentrations of the pure IsoPs ranging from 0.9 to 500 ng/mL. The curves were fitted 
using linear regression model with 1/X factors. The linearity of the method was assessed for each metabolite by evaluating the correlation 
coefficient (Table 3). The LOD and LOQ of our method were evaluated, and in general LOD corresponding to the lowest concentration had 
signal to noise ratio above 3 and LOQ corresponding to the lowest concentration had signal to noise ratio above 10. Both of these values however 
depended on the type of isoprostanoids. For PA derivatives the LOD values ranged from 0.24 ng/mL to 1 ng/mL and the LOQs from 0.12 ng/mL 
to 2 ng/mL. As shown in Table 3, the LOD values ranged from 0.49 ng/mL to 15.6 ng/mL and the LOQs from 0.98 ng/mL to 31.25 ng/mL. The 
sensitivity obtained for F2-IsoP, which is the main IsoP in the literature, is in agreement with LOQ previously reported by others  [29] [30]. The 
sensitivity observed was better than the isoprostanoids with derivatization, in particular for PA. The lack of sensitivity and specificity by PA 
derivatization indicates that it was not suited for the analysis of IsoPs and more so in biological samples, which often have complicated matrix 
structure that could further affect the precision of the measurement. 
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3.2 Plasma sample preparation and analysis   
The lipid portion of the tissues or cells was extracted using Folch solution in the presence of antioxidant (0.005% BHT). It is known 
approximately 70% of the IsoPs are conjugated to phospholipid through ester bond [31], therefore hydrolysis step is required to analyse the total 
concentration.  The lipid extract or fluid (except urine) was treated with 1 M KOH prepared in methanol for 30 minutes at 40 ºC. This step is not 
required for measurement of non-esterified IsoPs i.e. free form. A purification process is needed to reduce matrix effect and to increase 
sensitivity of the quantification by LC–MS/MS analysis. Different SPE cartridges were tested in this procedure namely, C18[32], HRX[33] and 
MAX[22]. It was found MAX cartridge, which is composed of mixed anionic exchange phase provided the cleanest sample and the best LC-
MS/MS evaluation. A part of the lipid extracts from SPE were taken for derivatization process. The data obtain from plasma with and without 
derivatization were compared (data not shown). Despite the peak response and area being bigger for the derivatized samples, the background 
noise of the chromatogram was much more compared to the non-derivatized samples. Moreover, the derivatization caused the formation of few 
additional peaks very close to the target ones, making it more difficult to differentiate for peak integration. This observation further support that 
derivatization procedure is not suitable for IsoP analysis by LC-MS/MS for plasma and likely for other biological samples. Therefore, in order to 
avoid overestimation in our quantification, we adopted the IsoP measurements without derivatization process in this study.  
 
3.3 Validation of sample processing 
3.3.1 Matrix effect and yield of extraction  
The efficiency of the sample processing was assessed by measuring the matrix effect and the extraction yield using plasma in triplicate. These 
two parameters were calculated for two concentrations of IsoPs (250 and 31.25 ng/mL). The peak areas of the chromatogram for each IsoP were 
compared before and after addition plasma extraction to obtain the matrix effect, as summarized in supporting material Table 1.  The matrix 
effect ranged between 51.4% to 92.7% for low concentration and between 56.7% to 77.5% for high concentration. The values were relatively 
homogeneous in each group of IsoP. The yield of extraction (supporting material Table 1) was calculated for each IsoP for two concentrations 
comparing the quantity recovered in presence of plasma to the native one. The yield ranged from 52.0% to 85.3% for low concentration and from 
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40.5% to 69.2% for high concentration. Surprisingly the yield extraction of F3t-IsoPs was above 100%, and no interference signal was observed 
for the non-spiked plasma extract; the reason for this observation is unknown.    
 
3.3.2 Performance of the method 
Repeatability and precision were then evaluated for intra- and inter-day at 3 concentrations: 3.91, 31.25 and 250 ng/mL (supporting material 
Table 2) were performed in triplicate. The intra-day accuracy ranged from 81.73% to 114.21% for all IsoP evaluated. The RSD values for 3 
injections were ≤ 8%. The inter-day variations were assessed by re-analyzing the samples every 15 days (n=2). The accuracies obtained were 
between 80.9% and 115.53% with a precision ≤ 15%. These data indicate that the method is highly reproducible for the 20 IsoP compounds 
analyzed. 
 
3.4 Application on various biological samples 
Our extraction and LC-MS/MS methods were applied to quantify non-enzymatic oxidized lipids from PUFAs in different biological samples. 
The different samples (Table 4) measured include human plasma and CSF, mice plasma, urine, liver, brain and muscle tissues A typical profile 
for human plasma is displayed in Figure 5. The structural matrix was taken into account for the quantity used for each type of samples and the 
size is shown in Table 4. Apart from CSF, IsoPs were detected and it appears to vary depending on the type of sample. No IsoPs were found in 
CSF, and it likely due to small volume used and concentration maybe below our limit of detection.  
The method developed was also used to perform the isoprostanoids profiles in the liver and brain of LDLR
-/-
 mice and to investigate if DHA 
supplementation could affect the profiles. The overall levels i.e. total summation of all the related isomers measured for F2-IsoPs (19 pg/mg vs 14 
pg/mg) and for F4-NeuroPs (19 pg/mg vs 17 pg/mg) in the liver and brain of control mice (white bars, Figures 6A and 6C) were slightly higher in 
the liver than the brain (+36% for F2-IsoP and +11% for F4-NeuroP). Furthermore, the total levels of F4-NeuroPs in the control mice liver and 
brain were similar to the levels of F2-IsoPs even though the concentration of DHA was 6 times and 34 times higher than AA in the liver and brain 
respectively (data not shown). Our observation suggest that the presence of high DHA concentration may contribute in protecting the liver and 
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brain from ROS attack despite it being more prone to peroxidation due to extra double bonds in the structure compared to AA [8]. When looking 
at the different isomers of the isoprostanoids (Figure 6B and 6D), it is interesting to note that the distribution of the different F2-IsoP isomers is 
slightly different in the liver and brain of the control mice with 15-epi-F2t-IsoP and 15-F2t-IsoP being more abundant in the brain; for the liver, 
the abundance of the different F2-isomers was as follows: 15-F2t<5-Epi-F2t>15-Epi-F2t>5-F2t.  
Among the F4-NeuroPs, the most abundant isomer was 4(RS)-4-F4t-NeuroP regardless of the tissue type. This finding is consistent with previous 
analysis performed in rat brain and heart tissues[34] .When the mice were supplemented with DHA (Figure 6, dark bars), the total level of F2-
IsoPs decreased in the brain (-40% for the sum of F2-IsoP) and the liver (-57% for the sum of F2-IsoP) whereas the total level of F4-NeuroPs 
increased by 51% in the brain and 247% in the liver. The concomitant decrease of F2-IsoPs and increase of F4-NeuroPs could be attributed at 
least in part by the replacement of AA by DHA in the membrane phospholipids. It should nevertheless be noted that the modulation of 
isoprostanoids profiles is much more pronounced in the liver than in the brain emphasizing the high “plasticity” of liver towards DHA 
supplementation. Consistently, correlations between levels of AA and F2-IsoP as well as DHA and F4-NeuroP were strong in the liver (R
2
=0.71 
and 0.96 respectively, Figure 7A and B) whereas they were much weaker in the brain (R
2
=0.02 and 0.16 respectively, data not shown).  
It should be noted in this report that we profiled the isoprostanoids in the liver and brain of an atherosclerotic mice and not normal mice. It is also 
anticipated that the profile of a normal mice may be different from our observation. Regardless, the objective of this study is to understand the 
differential changes between tissues. Our observation particularly displayed the importance of performing an integrated analysis of 
isoprostanoids levels since biological interpretation regarding tissue distribution and dietary modulation of lipid peroxidation is complex, and 
may lead to incorrect interpretation of experimental findings[10]. Moreover, the distribution of different types of isomers depends on the tissue 
type, which indicates the importance of tissue selection for studies evaluating bioactivity and organ crosstalk.  
In summary, we have described a LC-MS/MS methodology allowing simultaneous quantification of several isoprostanes derived from n-3 and n-
6 PUFA which are potential biomarkers in biological systems. Using the LC-MS/MS, we first characterized the analytical and quantification 
parameters of the 20 studied IsoPs and the 4 internal standards including LOD and LOQ concentration range. We optimized the sample 
preparation and the extraction process of these isoprostanoids which include Folch extraction, basic hydrolysis and SPE purification to obtain 
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low matrix effect and good yield of extraction. The method was validated on human plasma (repeatability and accuracy). The optimized 
chromatographic separation permits to separate nearly all the isomers in 30 minutes with a good sensitivity. We then applied this method to 
human samples (plasma and CSF) and mice samples (plasma, urine, liver, brain, muscle) to optimize the quantity required to be able to profile 
the isoprostanoids. Finally, the method was tested on brain and liver samples of LDLR
-/-
 mice with and without DHA supplementation to observe 
the change on the isoprostanoids profiles.  We found a variation in the distribution of different F2-IsoP isomers between tissues but not for F4-
NeuroP. DHA supplementation concomitantly increased F4-NeuroP levels.  OS is a key feature in a number of human diseases, since ROS are 
likely to be involved in all disease stages. Many of these diseases are associated to PUFA therefore it is important to identify and evaluate the 
IsoP compounds simultaneously, not only as reliable biomarkers but also for its functional roles in the PUFA metabolism; we believe that the 
information we obtained from such profiling will allow us to understand the interaction of the compounds in diet and disease studies. 
 
4. Conclusion 
 In this report, we developed a quick and robust method to determine multiple numbers of non-enzymatic oxidized lipid products of 
PUFAs, namely isoprostanoids in various biological sample in particular human plasma by LC-MS/MS. Unlike other reports, we were able to 
measure and incorporate new isoprostanoids from AdA and ALA as well as some isomers of AA, DHA and EPA into our method. However, it 
should be noted that not all 20 of the products determined were found in all biological samples therefore care must be taken when selecting them 
in metabolism studies. 
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Figure legends 
 
Figure 1. Chemical structure of isoprostanes derived from non-enzymatic oxidation of  n-6 PUFA, adrenic acid (AdA) and arachidonic acid 
(AA), and n-3 PUFA, -linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) measured in this study. 
 
Figure 2. Total ion current chromatogram of IsoP: with PA derivatization (A), with HP derivatization (B), and without derivatization (C) of the 
same sample mix. 
 
Figure 3. Chromatogram of selected reaction monitoring (SRM) of metabolites from each PUFA A: adrenic acid, B: arachidonic acid, C: -
linolenic acid, D: eicosapentaenoic acid and E: docosahexaenoic acid. The numbers indicated for each molecule refers to the compounds 
annotated in Table 1.  
 
Figure 4. Optimum chromatographic separation of diastereoisomers for 8-F3t-IsoP (a) and 8-epi-8-F3t-IsoP (b). The diastereoisomers of 5-F2t-
IsoP (c) and 5-epi-5-F2t-IsoP (d) were unable to resolve as well in the chromatographic analysis. 
 
Figure 5. Chromatogram of selected reaction monitoring (SRM) of metabolites detected in human plasma : 15-F2t-IsoP, 15-epi-15-F2t-IsoP (A) ; 
5-F2t-IsoP, 5-epi-5-F2t-IsoP (B) ; 10-F4t-NeuroP, 10-epi-10-F4t-NeuroP (C) ; 4(RS)-F4t-NeuroP (D) ; internal standard d4-15-F2t-IsoP (E). 
 
Figure 6. Isoprostanoids levels in the liver and brain of LDLR
-/-
 mice given either oleic acid rich sunflower oil (Ctrl, n=3) or a mixture of oleic 
acid rich sunflower oil and DHA rich tuna oil providing 2% of energy as DHA (DHA, n=3). The sum of F2-IsoPs and sum of F4-NeuroPs 
represents the ‘total’ sum of the isomers measured for the respective group. 
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Figure 7. Correlations between the levels of AA or DHA and the corresponding isoprostanoids (i.e. sum of F2-IsoPs and sum of F4-NeuroPs) in 
the liver (A and B).  
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Table 1. Selected reaction monitoring (SRM) of the isoprostanes  derived from polyunsaturated fatty acids. 
Compounds 
 
RT 
(min) 
Precursor 
ion 
(m/z) 
Product 
ion 
(m/z) 
F (V) 
 
CE (V) 
 
Adrenic acid      
Ent-7(RS)-7-F2t-dihomo-IsoP 
20.76 381 143 120 18 
17(RS)-F2t-dihomo-IsoP 20.90 381 337 120 12 
 
Arachidonic acid  
     
15-epi-15-F2t-IsoP 14.24 353 193 120 20 
15-F2t-IsoP 14.69 353 193 120 20 
5-F2t-IsoP 15.85 353 115 120 12 
5-epi-5-F2t-IsoP 16.01 353 115 120 12 
2,3-dinor-15-F2t-IsoP 8.29 325 237 100 5 
Ent-15(RS)-2,3-dinor-5,6-dihydro- 
15-F2t-IsoP 
 8.30 327 283 120 20 
      
d4-15-F2t-IsoP 14.61 357 197 120 20 
C21-15-F2t-IsoP 18.97 368 193 120 22 
      
alpha-Linolenic acid       
Ent-16-epi-16-F1t-PhytoP 6.66 327 283 120 15 
Ent-16-F1t-PhytoP 6.94 327 283 120 15 
9-F1t-PhytoP 7.30 327 283 120 15 
9-epi-9-F1t-PhytoP 7.58 327 283 120 15 
      
Eicosapentaenoic acid       
8-F3t-IsoP 10.70 351 127 120 18 
8-epi-8-F3t-IsoP 11.82 351 127 120 18 
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5-F3t-IsoP 11.48 351 115 120 15 
5-epi-5-F3t-IsoP 11.72 351 115 120 15 
      
Docosahexaenoic acid      
10-F4t-NeuroP 16.43 377 153 120 15 
10-epi-10-F4t-NeuroP 17.31 377 153 120 15 
4(RS)-F4t-NeuroP 19.50 377 101 120 15 
      
d4-10-epi-10-F4t-NeuroP                                          17.19 381 157 120 15 
d4-10-F4t-NeuroP 16.31 381 157 120 15 
d4-4(RS)-4-F4t-NeuroP 20.90 382 239 120 15 
The deuterated form of IsoP and NeuroP, and C21-15-F2t isoP were used as internal standards for quantification of samples in this study. IsoP: 
isoprostane; NeuroP: neuroprostane; F: Fragmentor; CE: collision energy; N : number.  
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Table 2. Selected reaction monitoring (SRM) of the derivatized  isoprostanes derived from polyunsaturated fatty acids.  
Compound 
 RT (min) 
Precursor ion  
(m/z) 
Product ion  
(m/z) 
F 
 (V) 
CE 
 (V) 
Adrenic acid 
Ent-7(RS)-7-F2t-dihomo-IsoP 24.17 455 109 130 30 
17(RS)-F2t-dihomo-IsoP 23.41 455 109 130 30 
 
Arachidonic acid 
15-epi-15-F2t-IsoP 14.73 427 109 120 25 
15-F2t-IsoP 15.34 427 109 120 25 
5-F2t-IsoP 18.32 427 109 120 30 
5-epi-5-F2t-IsoP 18.50 427 109 120 30 
Ent-15(RS)-2,3-dinor-5,6-dihydro-15-F2t-IsoP 8.89 401 109 120 30 
 
d4-15-F2t-IsoP 15.26 431 109 120 25 
C21-15-F2t-IsoP 20.83 442 109 120 20 
 
alpha-Linolenic acid       
Ent-16-epi-16-F1t-PhytoP 5.97 401 109 120 30 
Ent-16-F1t-PhytoP 6.21 401 109 120 30 
9-F1t-PhytoP 6.62 401 109 120 30 
9-epi-9-F1t-PhytoP 6.86 401 109 120 30 
      
Eicosapentaenoic acid       
8-F3t-IsoP 10.58 425 109 120 35 
8-epi-8-F3t-IsoP 11.91 425 109 120 35 
5-F3t-IsoP 12.77 425 109 130 30 
5-epi-5-F3t-IsoP 13.03 425 109 130 30 
      
Docosahexaenoic acid      
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10-F4t-NeuroP 16.80 451 109 120 20 
10-epi-10-F4t-NeuroP 18.17 451 109 120 20 
14(RS)-14-F4t-NeuroP 18.53 451 109 130 25 
4(RS)-F4t-NeuroP 23.81 451 109 130 25 
      
d4-10-epi-10-F4t-NeuroP                                          16.64 455 109 
 
120 20 
d4-10-F4t-NeuroP 18.04 455 109 120 20 
d4-4(RS)-4-F4t-NeuroP 23.90 455 109 140 30 
The deuterated form of IsoP and NeuroP, and C21-15-F2t isoP were used as internal standards for quantification of samples in this study. IsoP: 
isoprostane; NeuroP: neuroprostane; isofurane ; F: Fragmentor; CE: collision energy. 
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Table 3. Limit of detection (LOD) and limit of quantification (LOQ) of the pure compounds analyzed. 
 
Compound Linear regression R
2
 LOD 
(ng/mL) 
LOQ (ng/mL) IS 
Adrenic acid      
Ent-7(RS)-7-F2t-
dihomo-IsoP 
y = 0.0044 x - 0.0339 0.998 1.95 3.91 d4-15-F2t isoP 
17(RS)-F2t-
dihomo-IsoP 
y = 0.0065 x - 0.0639 0.998 7.81 15.63 d4-15-F2t isoP 
 
Arachidonic acid 
     
2,3-dinor-15-F2t-
IsoP 
y = 0.0079 x - 0.0558 0.998 0.98 1.95 d4-15-F2t isoP 
Ent-15(RS)-2,3-
dinor-5,6-dihydro-
15-F2t-IsoP 
y = 0.0079 x - 0.0747 0.998 3.91 7.81 d4-15-F2t isoP 
15-epi-15-F2t-IsoP 
y = 0.0024 x - 0.0183 0.998 1.95 3.91 d4-15-F2t isoP 
15-F2t-IsoP 
y = 0.0027 x - 0.0208 0.998 1.95 3.91 d4-15-F2t isoP 
5-F2t-IsoP 
y = 0.0032 x  - 0.0240 0.998 1.95 3.91 d4-15-F2t isoP 
5-epi-5-F2t-IsoP 
y = 0.0042 x - 0.0348 0.998 1.95 3.91 d4-15-F2t isoP 
 
Alpha-Linolenic 
acid 
     
Ent-16-epi-16-F1t-
PhytoP 
y = 0.0136 x - 0.1393 0.998 1.95 3.91 d4-15-F2t isoP 
Ent-16-F1t-PhytoP y = 0.0133 x - 0.1109 0.998 1.95 3.91 d4-15-F2t isoP 
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9-F1t-PhytoP y = 0.0166 x - 0.1316 0.998 1.95 3.91 d4-15-F2t isoP 
9-epi-9-F1t-PhytoP y = 0.0160 x – 0.1293 0.998 1.95 3.91 d4-15-F2t isoP 
Eicosapentaenoic acid     
8-F3t-IsoP 
y = 0.0042 x - 0.0314 0.998 0.98 1.95 d4-15-F2t isoP 
8-epi-8-F3t-IsoP 
y = 0.0035 x - 0.0299 0.998 0.98 1.95 d4-15-F2t isoP 
5-F3t-IsoP 
y = 0.0018 x - 0.0186 0.998 3.91 7.81 d4-15-F2t isoP 
5-epi-5-F3t-IsoP y = 0.0012 x - 0.0111 0.998 3.91 7.81 d4-15-F2t isoP 
Docosahexaenoic acid     
10-F4t-NeuroP 
y = 0.0017 x - 0.0117 0.998 0.49 0.98 d4-10-F4t-
NeuroP 
10-epi-10-F4t-
NeuroP 
y = 0.0023 x - 0.0162 0.998 0.98 1.95 d4-10-epi-10-
F4t-NeuroP 
14(RS)-14-F4t-
NeuroP 
y = 6.2450.10
-5
 x - 6.7300.10
-4
 0.998 15.63 31.25 d4-10-epi-10-
F4t-NeuroP 
 
 
4(RS)-F4t-NeuroP 
y = 1.8386.10
-4
 x - 0.0019 0.998 7.81 15.63 d4-4(RS)-F4t-
NeuroP 
The deuterated form of IsoP and NeuroP were used as internal standards to determine the LOD and LOQ of the analytes. IsoP: isoprostane; 
NeuroP: neuroprostane. 
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Table 4. Types of isoprostanes quantified in human and mice biological samples using the 
method described in Section 3. 
 
Biological samples Sample size IsoPs detected 
Human plasma 1 mL 15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, 5-
epi-5-F2t-IsoP, 10-F4t-NeuroP, 10-epi-10-F4t-
NeuroP, 4(RS)-F4t-NeuroP 
 
Human CSF 
 
600 µL n.d 
Mouse Plasma   200 µL 15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, 5-
epi-5-F2t-IsoP 
 
Mouse Urine  200 µL Ent 15 (RS) 2,3 dinor 5,6 dihydro 15-F2t-isoP,  
15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, 5-
epi-5-F2t-IsoP 
 
Mouse Liver 200 mg 15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, 5-
epi-5-F2t-IsoP, 10-F4t-NeuroP, 10-epi-10-F4t-
NeuroP, 4(RS)-F4t-NeuroP 
 
Mouse Brain 200 mg 15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, 5-
epi-5-F2t-IsoP, 10-F4t-NeuroP, 10-epi-10-F4t-
NeuroP, 4(RS)-F4t-NeuroP, Ent-7(RS)-F2t-
Dihomo IsoP 
 
Mouse Muscle 
 
200 mg 5-F2t-IsoP, 5-epi-5-F2t-IsoP 
n.d. not detected; IsoP: isoprostane; NeuroP: neuroprostane 
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Supporting material Table 1.  
Plasma matrix effect and extraction efficiency of healthy human plasma.  
Compound name Matrix effect Yield extraction 
250 ng/mL 31.25 ng/mL 250 ng/mL 31.25 ng/mL 
Adrenic acid     
Ent-7(RS)-F2t-dihomo 
IsoP 
66.8 ± 9.6 63.1 ± 8.2 63.2 ± 2.3 77.6 ± 1.2 
17(RS)-F2t-dihomo IsoP 68.2 ± 9.2 69.1 ± 8.4 62.9 ± 2.8 83.9 ± 2.5 
     
Arachidonic acid     
15-epi-15-F2t-IsoP 70.5 ± 9.2 74.1 ± 7.7 58.9 ± 2.5 73.2 ± 2.0 
15-F2t-IsoP 68.6 ± 9.7 73.2 ± 9.0 59.6 ± 2.0 69.9 ± 2.3 
5-F2t-IsoP 64.7 ±10.7 82.1 ± 7.6 61.3 ± 2.6 62.4 ± 10.5 
5-epi-5-F2t-IsoP 69.2 ± 9.5 64.9 ± 10.3 58.0 ± 3.0 72.3 ± 8.0 
2,3-dinor-15-F2t-IsoP 59.6 ± 8.2 57.0 ± 6.9 51.6 ± 0.9 71.1 ± 11.6 
Ent-15(RS)-2,3-dinor-
5,6-dihydro-15-F2t-IsoP 
 
62.5 ± 9.3 73.6 ± 2.4 57.9 ± 0.9 79.1 ± 5.5 
     
d4-15-F2t-IsoP 67.1 ± 8.8 69.8 ± 8.6 
C21-15-F2t-IsoP 61.2 ± 8.6 79.2 ± 9.9 
     
Alpha-Linolenic acid     
Ent-16-epi-F1t-PhytoP 58.0 ± 8.7 53.5 ± 6.1 40.5 ± 2.1 58.3 ± 5.7 
Ent-16-F1t-PhytoP 58.7 ± 8.6 53.8 ± 6.4 42.7 ± 1.6 60.4 ± 3.2 
9-F1t-PhytoP 56.7 ± 8.5 53.7 ± 5.5 46.7 ± 1.7 65.2 ± 7.3 
9-epi-9-F1t-PhytoP 
 
59.1 ± 8.9 51.8 ± 6.4 45.0 ± 1.2 67.1 ± 7.6 
     
Eicosapentaenoic acid     
8-F3t-IsoP 65.5 ± 8.8 57.8 ± 8.2 54.0 ± 2.1 74.2 ± 4.9 
8-epi-8-F3t-IsoP 64.5 ± 8.9 62.1 ± 6.2 55.5 ± 2.4 65.5 ± 3.4 
5-F3t-IsoP 59.9 ± 8.0 65.1 ± 6.4 104.9  ± 4.3 117.9  ± 5.8 
5-epi-5-F3t-IsoP 
 
64.7 ± 7.7 68.2 ± 8.9 112.0  ± 6.4 131.8  ± 0.6 
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Docosahexaenoic acid     
10-F4t-NeuroP 75.3 ± 9.7 68.2 ± 9.8 54.9 ± 2.5 74.0 ± 5.4 
10-epi-10-F4t-NeuroP 72.5 ± 9.1 64.6 ± 8.4 55.7 ± 2.5 77.4 ± 0.1 
14(RS)-14-F4t-NeuroP 77.3 ± 8.1 82.6 ± 7.1 58.9 ± 4.8 52.0 ± 10.6 
4(RS)-F4t-NeuroP 73.1 ± 11.1 92.7 ± 4.0 61.0 ± 3.9 76.6 ± 0.1 
     
d4-10-epi-10-F4t-NeuroP                                        66.2 ± 4.1 72.5 ± 7.2 
d4-10-F4t-NeuroP 73.5 ± 4.7 68.1 ± 7.6 
d4-4(RS)-F4t-NeuroP 64.8 ± 12.1 63.8 ± 7.4 
The matrix and extraction yield were tested by the addition of low and high concentration of 
the respective compounds as described in Section 2. IsoP: isoprostane; NeuroP: 
neuroprostane. 
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Supporting material Table 2 
Repeatability and accuracy of the method for isoprostanes evaluation in human plasma. 
Compound Nominal conc. 
(ng/mL) 
Intraday Interday 
Measured RSD % Accuracy % Measured RSD % Accuracy % 
Adrenic acid        
Ent-7(RS)-F2t-
dihomo-IsoP 
 
 
3.91 
31.25 
250 
3.91 ± 0.28 
31.31 ± 0.37  
256.91 ±1.65 
0.32 
0.24 
0.17 
102.28 
101.53 
102.77 
4.48 ± 0.81 
33.79 ± 0.67  
273.58 ± 4.50 
18.04 
1.97 
1.65 
114.61 
82.35 
111.12 
17(RS)-F2t-dihomo-
IsoP 
 
 
3.91 
31.25 
250 
n.d  
31.24 ± 1.77  
253.60 ±0.53 
n.d  
0.16 
0.11 
n.d  
96.37 
101.44 
n.d  
26.41 ± 0.83  
262.76 ± 7.84 
n.d  
3.13 
2.98 
n.d  
84.43 
105.10 
        
Arachidonic acid        
15-epi-15-F2t-IsoP 
 
 
3.91 
31.25 
250 
3.96 ± 0.54 
31.57 ± 1.04 
254.41 ± 1.72 
0.52 
0.42 
0.30 
108.20 
97.39 
101.77 
4.50 ± 0.18 
33.44 ± 0.50 
269.80 ± 10.52 
4.02 
1.50 
3.90 
115.29 
86.94 
104.69 
15-F2t-IsoP 
 
 
3.91 
31.25 
250 
4.10 ± 0.27 
30.94 ± 1.44 
257.20 ± 4.92 
0.47 
0.38 
0.27 
108.82 
100.42 
102.88 
4.21 ± 0.59 
32.60 ± 0.45 
275.25 ± 5.98 
13.98 
1.39 
2.17 
107.85 
84.51 
106.05 
5-F2t-IsoP 
 
 
3.91 
31.25 
3.64 ± 0.02 
31.48 ± 0.60  
0.49 
0.33 
93.26 
99.68 
4.14 ± 0.37 
30.02 ± 0.97  
8.91 
3.22 
105.95 
88.39 
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26 
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28 
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250 260.76 ±1.08 0.23 104.30 268.06 ± 3.60 1.34 107.19 
5-epi-5-F2t-IsoP 
 
 
3.91 
31.25 
250 
3.71 ± 0.13 
31.41 ± 0.86  
254.45 ±5.61 
0.35 
0.26 
0.17 
93.84 
102.67 
101.78 
3.79 ± 0.41 
32.24 ± 0.30  
271.10 ± 4.77 
0.71 
0.92 
1.76 
91.19 
80.90 
108.36 
2,3-dinor-15-F2t-IsoP 
 
 
 
3.91 
31.25 
250 
3.50 ± 0.11 
31.39 ± 0.20 
253.89 ± 1.57 
3.09 
0.62 
0.62 
87.01 
100.34 
101.56 
4.14 ± 0.52 
30.06 ± 0.49  
245.48 ± 8.11 
12.56 
1.64 
3.30 
105.99 
84.98 
98.61 
Ent-15 -(RS)-2,3-
dinor 5,6 dihydro-
15-F2t-IsoP 
 
 
3.91 
31.25 
250 
3.97 ± 0.32 
31.27 ± 0.71 
254.19 ± 1.94 
8.05 
2.27 
0.09 
110.80 
99.21 
101.67 
4.80 ± 0.41 
33.17 ± 1.22  
237.99 ± 9.28 
8.44 
3.68 
3.90 
115.53 
92.75 
96.48 
        
Alpha-Linolenic acid        
Ent-16-epi-16-F1t-
PhytoP 
3.91 
31.25 
250 
3.37 ± 0.25 
31.39 ± 0.27 
252.93 ± 2.70 
7.49 
0.86 
1.07 
81.73 
100.26 
101.17 
4.04 ± 0.19 
32.84 ± 0.55  
251.57 ± 7.61 
4.63 
1.68 
3.02 
103.49 
87.89 
100.06 
Ent-16-F1t-PhytoP 3.91 
31.25 
250 
3.66 ± 0.18 
31.43 ± 0.22 
254.35 ± 2.88 
4.93 
0.70 
1.13 
95.35 
100.12 
101.74 
3.94 ± 0.10 
31.82 ± 0.92  
246.90 ± 9.44 
2.56 
2.88 
3.82 
100.96 
87.51 
98.89 
9-F1t-PhytoP 3.91 
31.25 
250 
3.64 ± 0.09 
31.31 ± 0.04 
257.24 ± 3.60 
2.38 
0.13 
1.40 
90.53 
100.18 
102.90 
4.24 ± 0.02 
32.04 ± 0.87  
256.15 ± 8.56 
0.47 
2.71 
3.34 
108.65 
85.74 
101.28 
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9-epi-9-F1t-PhytoP 3.91 
31.25 
250 
3.57 ± 0.02 
31.31 ± 0.58 
256.35 ± 2.21 
0.61 
1.87 
0.86 
91.37 
99.36 
102.54 
4.44 ± 0.28 
31.25 ± 0.84  
253.11 ± 7.69 
6.22 
2.70 
3.04 
113.55 
85.27 
100.54 
        
Eicosapentaenoic acid       
8-F3t-IsoP 
 
 
3.91 
31.25 
250 
3.48 ± 0.14 
31.15 ± 0.61 
253.18 ± 1.67 
3.92 
1.96 
0.17 
89.71 
100.59 
101.27 
4.06 ± 0.77 
32.05 ± 0.69  
243.29 ± 8.38 
18.90 
2.16 
3.45 
103.87 
88.59 
97.93 
8-epi-8-F3t-IsoP 
 
 
3.91 
31.25 
250 
3.57 ± 0.13 
31.48 ± 0.85 
252.98 ± 3.52 
0.41 
0.31 
0.21 
94.08 
97.61 
101.19 
4.42 ± 0.29 
32.55 ± 1.19  
243.60 ± 4.45 
6.53 
3.66 
1.83 
113.12 
89.77 
97.99 
5-F3t-IsoP 
 
 
3.91 
31.25 
250 
3.85 ± 0.61 
31.02 ± 0.59 
254.47 ± 4.08 
0.86 
0.59 
0.40 
86.07 
99.26 
101.79 
3.60 ± 0.26 
30.36 ± 1.21 
226.63 ± 5.18 
7.17 
3.97 
2.29 
92.08 
89.52 
93.51 
5-epi-5-F3t-IsoP 
 
 
3.91 
31.25 
250 
3.75 ± 0.54 
31.19 ± 1.11 
254.04 ± 4.84 
1.48 
0.86 
0.61 
85.89 
102.31 
101.62 
3.95 ± 0.26 
30.20 ± 1.82 
232.31 ± 8.13 
6.57 
6.01 
3.50 
101.03 
88.80 
95.10 
Docosahexaenoic acid       
10-F4t-NeuroP 
 
 
3.91 
31.25 
250 
3.47 ± 0.20 
31.27 ± 0.96  
256.74 ± 1.01 
0.19 
0.16 
0.10 
93.71 
103.17 
102.70 
3.76 ± 0.11 
32.18 ± 0.37 
259.93 ± 3.98 
2.81 
1.16 
1.53 
96.17 
85.61 
102.25 
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Three nominal concentrations of the compounds were used to assess the stability of the compounds within the day (intraday) and between 15 
days intervals (interday). IsoP: isoprostane; NeuroP: neuroprostane; IsoF: isofuran.
10-epi-10-F4t-NeuroP 
 
 
3.91 
31.25 
250 
3.75 ± 0.16 
31.29 ± 0.16  
256.15 ± 3.60 
0.22 
0.17 
0.12 
95.14 
99.53 
102.46 
3.94 ± 0.47 
31.72 ± 0.70 
262.56 ± 1.97 
11.83 
2.22 
0.75 
100.92 
84.31 
102.93 
14(RS)-14-F4t-
NeuroP 
 
 
3.91 
31.25 
250 
n.d  
33.66 ± 0.83  
255.05 ± 9.44 
n.d  
5.49 
4.32 
n.d  
109.19 
102.02 
n.d  
29.42 ± 2.84  
258.99 ± 16.26 
n.d  
9.66 
6.25 
n.d  
94.15 
97.67 
4(RS)-F4t-NeuroP 
 
 
3.91 
31.25 
250 
n.d  
31.41 ± 2.40  
256.93 ± 3.24 
n.d  
2.03 
1.46 
n.d  
101.15 
102.77 
n.d  
35.16 ± 3.18  
261.07 ± 3.00 
n.d  
9.04 
1.15 
n.d  
93.60 
102.47 
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